{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"provenance":[],"authorship_tag":"ABX9TyMWvOUI5pgtGFl0tY1b5ltv"},"kernelspec":{"name":"python3","display_name":"Python 3"},"language_info":{"name":"python"}},"cells":[{"cell_type":"markdown","source":["\n","\n","\n","\n","\n","**Data Parser for grabbing clinical Trial eligibility criteria**"],"metadata":{"id":"gP2TuFIGHCL1"}},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"LCG0ta7s8ydz","executionInfo":{"status":"ok","timestamp":1699817685366,"user_tz":300,"elapsed":1095,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"fcfb8cfe-b009-4d3a-f24d-4590e0154ab8"},"outputs":[{"output_type":"stream","name":"stdout","text":["Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n","200\n","Wrote successfully\n"]}],"source":["# CS 333 Final Project Data Parser\n","\n","\n","import requests\n","import json\n","\n","from google.colab import drive\n","drive.mount('/content/drive')\n","\n","# api_url = 'https://clinicaltrials.gov/api/query/full_studies?expr=heart+attack&aggFilters=results:with,status:com&min_rnk=1&max_rnk=2&fmt=json'\n","\n","# single study\n","# https://clinicaltrials.gov/study/NCT05940077?rank=1&viewType=Table&aggFilters=results:with,status:com&tab=results\n","api_url = 'https://clinicaltrials.gov/api/v2/studies?aggFilters=results:with,status:com'\n","\n","\n","params = {\n","}\n","\n","response = requests.get(api_url)\n","\n","if response.status_code == 200:\n","    print(response.status_code)\n","else:\n","    print(\"Error: \", response.status_code, response.text)\n","\n","with open(\"/content/drive/My Drive/outfile_test.json\", \"w\") as outfile:\n","    raw_json = response.json()\n","    json_object = json.dumps(raw_json, indent=4)\n","\n","    # study_data = {}\n","\n","    # study_data['identificationModule'] = raw_json['studies'][0]['protocolSection']['identificationModule']\n","\n","    # study_data['eligibilityModule'] = raw_json['studies'][0]['protocolSection']['eligibilityModule']\n","\n","    # all_data = json.dumps(study_data, indent=4)\n","\n","    # outfile.write(all_data)\n","\n","    outfile.write(json_object) # (testing)\n","\n","    print(\"Wrote successfully\")\n","\n","\n","\n"]},{"cell_type":"code","source":["api_url = 'https://clinicaltrials.gov/api/v2/studies?aggFilters=results:with,status:com'\n","\n","params = {\n","}\n","\n","response = requests.get(api_url)\n","\n","if response.status_code == 200:\n","    print(response.status_code)\n","else:\n","    print(\"Error: \", response.status_code, response.text)\n","\n","with open(\"/content/drive/My Drive/outfile.json\", \"w\") as outfile:\n","    raw_json = response.json()\n","    json_object = json.dumps(raw_json, indent=4)\n","\n","    study_keys = {'studies': []}\n","\n","    for study in raw_json['studies']:\n","      study_data = {}\n","\n","      study_data['identificationModule'] = study['protocolSection']['identificationModule']\n","\n","      study_data['eligibilityModule'] = study['protocolSection']['eligibilityModule']\n","\n","      study_keys['studies'].append(study_data)\n","\n","    outfile.write(json.dumps(study_keys, indent=4))\n","\n","    # outfile.write(json_object) # (testing)\n","\n","    print(\"Wrote successfully\")"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"4RYhXnHP_yU5","executionInfo":{"status":"ok","timestamp":1699817588678,"user_tz":300,"elapsed":261,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"e24e8f91-2482-4b98-f810-604b4863424b"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["200\n","Wrote successfully\n"]}]},{"cell_type":"markdown","source":["**Code for performing named entity recognition on very simple labeled patient health records**"],"metadata":{"id":"juMBsraWG-b8"}},{"cell_type":"code","source":["import json\n","import spacy\n","\n","from google.colab import drive\n","drive.mount('/content/drive')\n","\n","with open(\"/content/drive/My Drive/consolidated_chia_outfile.json\", \"r\") as outfile:\n","  data = json.load(outfile)\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"1-zT0KpAHPeH","executionInfo":{"status":"ok","timestamp":1700447068085,"user_tz":300,"elapsed":1077,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"4b682813-d8dd-479b-eaa3-c4a7863f244d"},"execution_count":41,"outputs":[{"output_type":"stream","name":"stdout","text":["Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"]}]},{"cell_type":"code","source":["!python -m spacy download en_core_web_lg"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"LJzbpHjcsS9L","executionInfo":{"status":"ok","timestamp":1700443142351,"user_tz":300,"elapsed":39622,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"ec5a847e-1d9c-4f80-8298-710fe523943c"},"execution_count":3,"outputs":[{"output_type":"stream","name":"stdout","text":["2023-11-20 01:18:25.049429: E tensorflow/compiler/xla/stream_executor/cuda/cuda_dnn.cc:9342] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n","2023-11-20 01:18:25.049489: E tensorflow/compiler/xla/stream_executor/cuda/cuda_fft.cc:609] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n","2023-11-20 01:18:25.049519: E tensorflow/compiler/xla/stream_executor/cuda/cuda_blas.cc:1518] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n","2023-11-20 01:18:26.275950: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT\n","Collecting en-core-web-lg==3.6.0\n","  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_lg-3.6.0/en_core_web_lg-3.6.0-py3-none-any.whl (587.7 MB)\n","\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m587.7/587.7 MB\u001b[0m \u001b[31m2.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hRequirement already satisfied: spacy<3.7.0,>=3.6.0 in /usr/local/lib/python3.10/dist-packages (from en-core-web-lg==3.6.0) (3.6.1)\n","Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.0.12)\n","Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (1.0.5)\n","Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (1.0.10)\n","Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.0.8)\n","Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.0.9)\n","Requirement already satisfied: thinc<8.2.0,>=8.1.8 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (8.1.12)\n","Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (1.1.2)\n","Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.4.8)\n","Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.0.10)\n","Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (0.9.0)\n","Requirement already satisfied: pathy>=0.10.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (0.10.3)\n","Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (6.4.0)\n","Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (4.66.1)\n","Requirement already satisfied: numpy>=1.15.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (1.23.5)\n","Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.31.0)\n","Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (1.10.13)\n","Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.1.2)\n","Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (67.7.2)\n","Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (23.2)\n","Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.3.0)\n","Requirement already satisfied: typing-extensions>=4.2.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (4.5.0)\n","Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.3.2)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (3.4)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.0.7)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2023.7.22)\n","Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.2.0,>=8.1.8->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (0.7.11)\n","Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.2.0,>=8.1.8->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (0.1.3)\n","Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.10/dist-packages (from typer<0.10.0,>=0.3.0->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (8.1.7)\n","Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<3.7.0,>=3.6.0->en-core-web-lg==3.6.0) (2.1.3)\n","Installing collected packages: en-core-web-lg\n","Successfully installed en-core-web-lg-3.6.0\n","\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n","You can now load the package via spacy.load('en_core_web_lg')\n"]}]},{"cell_type":"code","source":["data[\"NCT00894712_inc\"][\"Annotations\"][0]"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":35},"id":"enwnprhQtFmu","executionInfo":{"status":"ok","timestamp":1700443182443,"user_tz":300,"elapsed":10,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"1fe69529-605d-4ff2-82c5-da78d45669e3"},"execution_count":4,"outputs":[{"output_type":"execute_result","data":{"text/plain":["'Procedure 10 24--*--pathologically'"],"application/vnd.google.colaboratory.intrinsic+json":{"type":"string"}},"metadata":{},"execution_count":4}]},{"cell_type":"code","source":["data[\"NCT00894712_inc\"][\"Text\"]"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":154},"id":"B5DOx2KWxhst","executionInfo":{"status":"ok","timestamp":1700443197976,"user_tz":300,"elapsed":141,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"cc84a478-f0fc-458e-fe35-a0ec6e550348"},"execution_count":5,"outputs":[{"output_type":"execute_result","data":{"text/plain":["'Must have pathologically confirmed invasive adenocarcinoma or ductal carcinoma in situ of the breast. . Patients must have undergone segmental mastectomy (i.e., lumpectomy). . Patients must not have received prior radiation therapy to the breast. . Patients must not have active local-regional disease prior to registration. . Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment. Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant. They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy. . Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. . All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines. . '"],"application/vnd.google.colaboratory.intrinsic+json":{"type":"string"}},"metadata":{},"execution_count":5}]},{"cell_type":"code","source":["from spacy.tokens import DocBin\n","\n","# nlp = spacy.blank(\"en\")\n","\n","nlp = spacy.load(\"en_core_web_lg\")\n","\n","doc_bin = DocBin()"],"metadata":{"id":"LcH_gi14y0Qr","executionInfo":{"status":"ok","timestamp":1700443211481,"user_tz":300,"elapsed":4561,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}}},"execution_count":6,"outputs":[]},{"cell_type":"code","source":["# training from chia data\n","from spacy.util import filter_spans\n","\n","training_data = []\n","\n","for example in data:\n","\n","  if \"Text\" not in data[example] and \"Annotations\" not in data[example]:\n","    continue\n","\n","  temp_lst = []\n","\n","  text = data[example][\"Text\"]\n","  text = text.replace(\".\", \" \")\n","  text = text.strip()\n","\n","  if text == '.' or text == '' or text == ',' or text == ':':\n","    continue;\n","\n","  labels = []\n","  for entity in data[example][\"Annotations\"]:\n","    start = entity.split('--*--')[0].split(' ')[1]\n","    end = entity.split('--*--')[0].split(' ')[2]\n","    label = entity.split('--*--')[0].split(' ')[0]\n","    labels.append((start, end, label))\n","\n","  doc = nlp.make_doc(text)\n","  ents = []\n","\n","  for start, end, label in labels:\n","    if start.isdigit() and end.isdigit():\n","      span = doc.char_span(int(start), int(end), label=label, alignment_mode=\"contract\")\n","      print(span)\n","      if span is None:\n","        print(\"Skipping entity\")\n","      else:\n","        ents.append(span)\n","  filtered_ents = filter_spans(ents)\n","  doc.ents = filtered_ents\n","  doc_bin.add(doc)\n","\n","doc_bin.to_disk(\"train.spacy\")\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"3hkxJKNtUE61","executionInfo":{"status":"ok","timestamp":1700447212258,"user_tz":300,"elapsed":25018,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"b8e0d557-357c-41db-e4be-1a68d16dcc86"},"execution_count":45,"outputs":[{"output_type":"stream","name":"stdout","text":["\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n","infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding\n","immunomodulatory therapy\n","antineoplastic or immunomodulatory therapy\n","past 12 months\n","IFN\n","anti hepatitis B virus\n","resistance\n","NAs drug\n","Patients who can't come back to clinic for follow-up on schedule\n","Osteonecrosis\n","decompression surgery\n","planned\n","autologous stem cell transplant\n","Unable to participate\n","administrative reasons\n","Psychiatric troubles\n","Pain at rest\n","critical limb ischemia\n","Unable to walk\n","wheelchair subjects\n","PD\n","by a neurologist\n","by a neurologist\n","None\n","Skipping entity\n","30 to 85\n","modified Hoehn and Yahr (\n",") stage 1 5 to\n","  able and willing to give written consent for participation in the\n","  able and willing to give written consent for participation in the\n",";   living at home in the\n","for 30\n","Ulcerative colitis\n","moderate to severe\n","clinical remission\n","by the first course of corticosteroids\n","first course of corticosteroids\n","first course\n","corticosteroids\n","without\n","steroid\n","during last 1 year\n","Endoscopic Mayo subscore\n",">0\n","chemotherapy\n","unresectable disease\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","active or\n","HIV\n","hepatitis\n","None\n","Skipping entity\n","active hepatitis\n","None\n","Skipping entity\n","hepatitis\n","None\n","Skipping entity\n","active hepatitis\n","liver\n","None\n","Skipping entity\n","psychiatric\n","interfere with\n"," \n","None\n","Skipping entity\n","None\n","Skipping entity\n","reproductive\n","effective contraceptive\n","None\n","Skipping entity\n","concurrent\n",", which in the judgment of the\n","entry into this\n","inappropriate\n","treatment\n","two weeks or more\n","Cushing's syndrome\n","Addison's disease\n","diabetes mellitus type 1\n","leukaemia\n","pernicious anaemia\n","malabsorption syndromes\n","chronic liver disease\n","rheumatoid arthritis\n","immunosuppressive\n","cyclosporine\n","calcium antagonists\n","anti-epileptics\n","gingival hypertrophy\n","anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive\n","bone metabolism\n","anticoagulant\n","steroid\n","prednisolone\n",">3 months\n","anticonvulsants\n","immunosuppressants\n","anticoagulant medications, long-standing steroid medications -i e  equal or more 2 5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants)\n","Hepatitis\n","HIV\n","local radiation therapy\n","last five years\n","by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed\n","periodontal lesion\n","edentulous\n","Completely\n","With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e g  sharp knife edge ridge)\n","clenching habits\n","bruxism\n","Smokers\n","cigarettes\n","alcohol\n",">2 units/day\n","Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial\n","Patients unable or not willing to return for follow-ups\n","NA\n","Intracranial infection\n","circulatory system\n","None\n","Skipping entity\n","respiratory and circulatory system\n","Hematologic\n","as\n",", hepatitis B\n",", hepatitis C\n","None\n","Skipping entity\n","   \n","None\n","Skipping entity\n","and metabolic\n","previous\n","brain surgery\n","cognitive impairment\n","< 120 points\n","Mattis Dementia Rating Scale\n","moderate-to-severe\n","depression\n","> 25 points\n","Beck Depression Inventory\n","brain atrophy\n","magnetic resonance imaging\n","other medical or psychiatric coexisting disorders that could increase the surgical risk or interfere with completion of the trial\n","surgery\n","being prepared for\n","after surgery\n","congenital anomalies\n","chromosomal anomalies\n","heart defects\n","None\n","Skipping entity\n","Premenopausal\n","women\n","old\n","18-35 years\n","FSH levels\n","< 10 mIU/ml\n","AFC\n","> 10\n","Regular cycles\n","BMI\n","< 28\n","Signed informed consent\n","NA\n","ages\n","7 and 75 years\n","disability\n","dystonia\n","segmental\n","generalized\n","primary\n","generalized or segmental\n","optimal\n","pharmacologic treatment\n","disease duration\n","at least 5 years\n","cerebral palsy\n","Patients' curator must be able to give voluntary\n","Patients' curator must be able to give voluntary\n","PCOS\n","gonadotrophins\n","Allergy\n","Concomitant participation in other trial\n","neonates\n","Nonsurgical\n","babies\n","up to age 6 months\n","age\n","INR\n","1 5 or more\n","plasma infusion\n","need\n","cauda equina\n","conus\n","lesion\n","cauda equina or conus\n","currently\n","ventilator\n","colostomy\n","regular bowel care\n","do not perform\n","skin breakdown\n","pressure sores\n","not\n","speak English\n","under 19 years\n","old\n","pregnant\n","think you might be\n","pregnant\n","psychiatric condition\n","substance abuse\n","currently\n","medications containing lidocaine\n","lidocaine\n","allergy\n","pregnant\n","nursing\n","woman\n","pregnant or nursing\n","illness\n","concomitant\n","serious\n","malignant tumor\n","any kind\n","history of\n","hypersensitivity\n","test drugs\n","serious\n","bleeding\n","during the course of the ulcer\n","previous\n","gastric surgery\n","bismuth salts\n","PPIs\n","antibiotics\n","in the previous month\n","bismuth salts, PPIs, or antibiotics\n","anti-coagulation therapy\n","rivaroxaban\n","apart from\n","Hypersensitivity\n","allergy\n","factor Xa inhibitors\n","Hypersensitivity or allergy\n","Acute bacterial endocarditis\n","Bleeding disorder\n","active bleeding\n","Gastrointestinal ulcer\n","Hepatic dysfunction\n","bleeding risk\n","increased\n","Renal failure\n","dialysis\n","Pregnancy and breast feeding\n","Gastrectomy\n","biliopancreatic diversion\n","re-routing\n","resection\n","small intestines\n","resection or re-routing\n","Feeding tube\n","blood donation\n","alanine-aminotransferase\n","ALAT\n","aspartate-aminotransferase\n","ASAT\n","gamma-glutamyl transferase\n","gammaGT\n","alkalic phosphatase\n","AP\n","bilirubin\n","amylase\n","lipase\n","cystatin C\n","creatinine\n","white blood cell count\n","haemoglobin\n","platelet count\n","prothrombin time,\n","aPTT\n","fibrinogen\n","thrombin time\n","factors II\n","alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time, factors II,V,VII and X\n","Abnormalities\n","Use of therapeutic or recreational drugs influencing plasmatic coagulation\n","19-65 years\n","age\n","ASA physical status classification\n","I or II\n","total hip replacement\n","Scheduled for\n","diagnostic\n","therapeutic\n","colonoscopy\n","diagnostic or therapeutic\n","new relationship\n","no more than six months prior to study entry\n","remaining in Montreal\n","for at least 1 year\n","Plan on\n","plan on\n","having continued sexual contact with partner\n","Be willing to comply with study procedures\n","vitamin B12 deficiency\n","suspected\n","plasma vitamin B12\n","below the reference interval\n","<200 pmol/L\n","1\n","2\n","  \n","None\n","Skipping entity\n","C\n",")\n","None\n","Skipping entity\n","gestational age\n","between 27 to 34 weeks\n","PPROM\n"," Cephalic\n"," Clear amniotic\n","4  Oral\n",">\n","5  Near distance from the hospital (the patient can reach hospital within one\n","5  Near distance from the hospital (the patient can reach hospital within one\n","  6  Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at\n","  6  Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at\n","and fetal\n","None\n","Skipping entity\n","after hospitalization for 72\n","after\n","7  Maternal and fetal\n","Allergic\n","study drugs\n","asthma\n","COPD\n","severely\n","respiratory depressed\n","hepatic insufficiency\n","Epileptic status\n","Intracranial lesion\n","intracranial pressure\n","increased\n","Acute abdomen\n","paralytic ileus\n","suspicious ileus\n","Pregnant\n","lactating\n","None\n","Skipping entity\n","H  pylori related\n","chronic gastritis\n","peptic ulcers\n","aged\n","greater than 20 years old\n","eradication therapy\n","willing to\n","traumatic spinal cord injury\n","at least one year ago\n","regular bowel care routine\n","at least four weeks\n","tetraplegia\n","complete\n","at least 3 months\n","Age\n","from 18 to 74 years\n","Body mass index\n","BMI\n","from 18 to 35kg/m2\n","consent as documented by signature\n","not\n","have been\n","vaccinated\n","HPV-Gardasil-9\n","Any history\n","anal cancers\n","pregnant\n","plan on immediately becoming\n","pregnant\n","ileus\n","known\n","suspected\n","bowel obstruction\n","known or suspected\n","active\n","bowel inflammation\n","pregnancy\n","serious medical conditions\n","liver diseases\n","cardiac, renal, liver diseases\n","history of\n","prior\n","rectal surgery\n","colonic or rectal surgery\n","inability to obtain valid data from\n","pregnant\n","nursing\n","able to give written informed consent\n","not\n","1\n","rupture of membranes\n","equivocal\n"," advanced\n"," intrauterine\n","4  vaginal\n","None\n","Skipping entity\n","fetal heart\n","5  non\n","5  non\n","5  non\n","osteoarthritis\n","hip\n","secondary to degeneration\n","degeneration\n","inflammatory arthritis\n","gouty arthritis\n","acetabular dysplasia\n","osteonecrosis\n","femoral head\n","undergoing\n","primary\n","unilateral\n","minimally invasive THA\n","acetabular dysplasia or osteonecrosis\n","Age\n","> 18 years\n","< 90 years\n","Failure\n","medical treatment\n","rehabilitation\n","medical treatment or rehabilitation\n","Hemoglobin\n","> 11g/dl\n","non-steroid anti-inflammatory agent\n","one week before operation\n","operation\n","No\n","Aged\n","at least 18 years\n","Body mass\n","25-35 kg/\n","caffeinated\n","willing to be\n","   Non-\n","Veteran\n","Veterans Health Administration healthcare system\n","Age\n","18 years\n","chronic heart failure\n","American Heart Association Stage\n","C-D\n","LVEF\n","<45%\n","No\n","change\n","cardiac medications\n","for 4 weeks prior to randomization\n","randomization\n","Ability to provide informed consent\n","obstructive sleep apnea\n","severe\n","Moderate\n","apnea-hypopnea index\n","AHI\n","15 events per hour,\n","central AHI\n",">5 events/hour\n","apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour\n","central or mixed central and obstructive sleep apnea\n","Moderate to severe\n","allergy to nickel\n","nickel\n","bowel\n","bowel\n","None\n","Skipping entity\n","bowel\n","systemic\n","ischemic\n","None\n","Skipping entity\n","inflammatory bowel\n","extensively\n"," Patient is participating in another clinical trial which may affect this study's\n"," Patient is participating in another clinical trial which may affect this study's\n","steroid\n","None\n","Skipping entity\n","has contraindications to general\n","to general\n","sphincter\n","local disease in the\n","of\n","or\n","Informed consent\n","type 2 diabetes\n","HbA1c\n","> 48 mmol/mol\n","Age\n","older than 30 years\n","liver cirrhosis\n","Hepatocellular Carcinoma\n","malignancies\n","Patients with other factors causing liver diseases\n","Pregnant and lactating women\n","HIV infection\n","concomitant\n","congenital immune deficiency diseases\n","diabetes\n","autoimmune diseases\n","organ dysfunctions\n","serious\n","complications\n","infection\n","hepatic encephalopathy\n","hepatorenal syndrome\n","gastrointestinal bleeding\n","infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding\n","immunomodulatory therapy\n","past 12 months\n","antineoplastic or immunomodulatory therapy\n","Patients who can't come back to clinic for follow-up on schedule\n","homolateral\n","opioid consumption\n","habitual\n","alcoholics addiction\n","ICU postoperative recovery\n","kidney failure\n","creatinin\n","creatinin <clearance\n","30 ml/h\n","> 2 g/dl\n","hepatic failure\n","cholinesterase\n","< 2000 UI\n","creatinin > 2 g/dl, creatinin <clearance 30 ml/h\n","cardiac arrhythmias\n","Epilepsy\n","Psychiatric, cognitive disorders\n","mental retardation\n","Coagulopathies\n","INR\n","> 2\n","activated partial thromboplastin time -\n","sec\n","INR > 2, activated partial thromboplastin time - aPTT>44 sec\n","platelet count\n","less than 100 000/mm3\n","BMI\n","> 30\n","Allergies\n","study drugs\n","hip\n","At the cluster level, ED physicians practicing at a participating site will be eligible\n","seen by a participating ED physician will be\n","At the cluster level\n","At the patient\n","At the patient\n","At the cluster level\n","non-Burkitt B-lineage ALL\n","Confirmed\n","1 to 17 years\n","age\n","Renal function\n","within normal range for age\n","Liver function\n","within normal range for age\n","Able to participate\n","treatment\n","full 2 years\n","Preoperative\n","Hemoglobin\n","<U+2266>11 g/dl\n","infection\n","intraarticular fracture\n","affective hip\n","infection or intraarticular fracture\n","History\n","Renal function deficiency\n","GFR\n","<30 ml/min/1 73m2\n","GFR <30 ml/min/1 73m2\n","liver enzyme\n","Elevated\n","aspartate transaminase (AST)/ alanine transaminase(ALT) level\n","more than twice normal range\n","history\n","liver cirrhosis\n","impaired liver\n","None\n","Skipping entity\n","total bilirubin level\n","coagulopathy\n","long-term use\n","anticoagulant\n","long-term use anticoagulant\n","deep vein thrombosis\n","ischemic heart disease\n","stroke\n","Contraindications\n","tranexamic acid\n","floseal\n","rivaroxaban\n","tranexamic acid, floseal, or rivaroxaban\n","Allergy\n","tranexamic acid\n","floseal\n","rivaroxaban\n","excipients\n","tranexamic acid, floseal, rivaroxaban, or the excipients\n","heparin-induced thrombocytopenia (HIT)\n","History\n","Coagulopathy\n","bleeding tendency\n","organ dysfunction\n","cirrhosis\n","bone marrow suppression\n","cirrhosis, bone marrow suppression\n","Coagulopathy or bleeding tendency\n","active\n","bleeding disorder\n","intracranial hemorrhage\n","upper gastrointestinal bleeding\n","hematuria\n","intracranial hemorrhage, upper gastrointestinal bleeding, hematuria\n","allergies\n","materials of bovine origin\n","Type 1 diabetes\n","insulin\n","Treatment\n","Body weight\n","> 140 kg\n","HbA1c\n","> 75 mmol/mol\n","GLP-1 analogues\n","Dipeptidyl peptidase-4 inhibitors\n","glitazones\n","Pancreatitis\n","Chronic kidney disease\n","Hepatic disease\n","Inflammatory bowel disease\n","Osteoporosis\n","medullary thyroid carcinoma\n","personal history\n","Family\n","Family or personal history\n","glucocorticoids\n","Treatment\n","Hormone replacement therapy\n","Diabetic gastroparesis\n","Pregnancy\n","lactation\n","CHB\n","NAs\n","more than 12 months\n","Hepatitis B e antigen\n","None\n","Skipping entity\n","anti-HBeAg\n","positive\n","None\n","Skipping entity\n","Hepatitis B surface antigen\n","HBsAg\n","positive\n","<1500 IU/mL\n","Hepatitis B virus DNA\n","not\n","over 18 years old\n","years old\n","non-emergency\n","non-\n","None\n","Skipping entity\n","3  Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study\n","Hospitalization\n","acute decompensated HF\n","within previous 30 days\n","Hospitalization\n","myocardial infarction\n","cardiac surgery\n","within previous 90 days\n","myocardial infarction or cardiac surgery\n","left ventricular assist device\n","heart transplantation\n","hypertension\n","Poorly controlled\n","diabetes\n","Poorly controlled\n","HbA1c\n","> 9 0\n","renal failure\n","Severe\n","estimated glomerular filtration rate\n","<30 ml/min\n","stroke\n","functional impairment\n","other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records\n","chronic insomnia\n","sleep duration\n","<4 hours\n","daytime sleepiness\n","Epworth Sleepiness Scale\n","score 18 or higher\n","a report of falling asleep driving during the previous year, and deemed a safety risk by study physician\n","oxyhemoglobin saturation\n","resting\n","Awake\n","<89%\n","Pregnancy\n","Smoking by subject or other person in the subject's bedroom, or other open flame in bedroom\n","positive airway pressure device\n","bi-level positive airway pressure\n","adaptive servo-ventilation\n","supplemental oxygen therapy\n","continuous or bi-level positive airway pressure or adaptive servo-ventilation\n","pregnancy\n","breastfeeding\n","diabetes mellitus\n","heart disease\n","stroke\n","hypertension\n","malabsorption syndromes\n","GERD\n","history of\n","ulcer\n","illness that may affect the study outcomes\n","pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer\n","illness that may affect the study outcomes or would make participation potentially harmful\n","hepatic\n","None\n","Skipping entity\n","(liver function\n","> twice the normal\n","renal\n","None\n","Skipping entity\n","(\n","> 1 1 mg/\n","fasting plasma\n","in the diabetic\n","(>/= 126 mg/\n","blood\n","> 140/90\n","None\n","Skipping entity\n","drug\n","medications that could interfere with the\n","None\n","Skipping entity\n",", quinolone\n",", monoamine oxidase\n",",\n",",\n",",\n",", growth\n",",\n","bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone,\n","medical history\n","F\n","age\n","18 to 70\n","American Society of Anesthesiologists (ASA)\n","I e II\n","breast cancer\n","DIN\n","2 e 3\n","LIN\n","2 e 3 sec\n","nipple-sparing mastectomy\n","scheduled for\n","simple mastectomy\n","skin-sparing mastectomy\n","skin-reducing mastectomy\n","lymphnode biopsy\n","axillary dissection\n","DIN 2 e 3, o LIN 2 e 3 sec  Tavassoli\n","sub-pectoral prosthetic reconstruction\n","immediate\n","signed informed consent\n","Age\n","less than one year\n","greater than/equals to 18 years\n","age\n","Previous\n","treatment\n","cytotoxic agents\n","high-dose steroids\n","cytotoxic agents or high-dose steroids\n","Mixed phenotype acute leukemia\n","MPAL\n","ALL\n","secondary\n","malignancy\n","secondary malignancy\n","Doubtful compliance\n","unable to afford full course of therapy\n","ED physicians who work casually (less than 0 25 Full Time Equivalent)\n","ED Physicians who are routinely using U/S guided RA for hip fracture patients, or decline participation in the trial\n","less than 65\n","'\n","None\n","Skipping entity\n","on initial\n","on initial\n","None\n","Skipping entity\n","or\n","communication\n","communication\n","(critically\n",",\n",", language\n","(critically ill, unconscious, language\n","with\n","to\n","or local\n","to narcotics or local\n","; or\n","e g  \n",",\n",",\n","e g  warfarin, dabigatran,\n","with hip\n","None\n","Skipping entity\n","not requiring\n","None\n","Skipping entity\n","(e g  greater trochanter\n","with hip fractures not requiring\n","with hip fractures not requiring\n","adenocarcinoma of stomach\n","unresectable\n","Pathologically\n","proven\n","None\n","Skipping entity\n","uni-dimensionally\n","longest\n","conventional CT\n","x-\n","physical\n","spiral CT\n","longest\n","(at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT\n","  \n","18 to 70 years\n","  Estimated life\n","of more than 3\n","  ECOG performance\n","of 2 or\n","bone marrow\n","  \n","neutrophil count\n","ANC]\n",",\n","≥9 0\n",",and\n","None\n","Skipping entity\n","neutrophil count [ANC] ≥1,500/µL, hemoglobin ≥9 0 g/dL,and platelets\n","kidney\n",")   \n","(serum\n","< 1 5\n","liver\n","/dL)   \n","(serum total\n","< 2 times the upper normal\n","(UNL); serum transaminases\n","with liver\n","levels <3 times [<5 times for patients with liver\n","(serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver\n","prior\n",")   \n","None\n","Skipping entity\n","prior adjuvant\n","None\n","Skipping entity\n","at least 6 months before\n",", prior adjuvant\n"," (\n","with\n","None\n","Skipping entity\n","S-1 or camptothecin\n","was\n","No prior\n","for at least 4 weeks before\n","None\n","Skipping entity\n",")\n","before\n","was\n","but prior adjuvant chemotherapy finished at least 6 months before enrollment was\n","before\n","systemic disease\n","Clinically significant\n","diabetes\n","metabolic syndrome\n","immunological diseases\n","diagnosed thrombophilia\n","porphyria\n","medical condition\n","low-molecular weight heparin\n","diabetes, metabolic syndrome, immunological diseases, diagnosed thrombophilia, porphyria, or any other medical condition requiring the use of low-molecular weight heparin therapy\n","Clinically significant systemic disease\n","Polycystic ovary syndrome (PCOS)\n","Rotterdam Consensus Criteria\n","European Society of Human Reproduction and Embryology [ESHRE]/American Society for Reproductive Medicine [ASRM], 2003\n","Poor ovarian response (POR)\n","European Society of Human Reproduction and Embryology (ESHRE) Criteria\n","RIF (repeated implantation failure)\n","greater than or equals to (>=) 2\n","previous failed embryo transfers\n","Endometriosis\n","III-IV stage\n","adenomyosis\n","Clinically significant\n","exam\n","ultrasound\n","salpingitis\n","hydrosalpynx\n","ovarian cysts\n","evidence\n","exam or ultrasound\n","findings\n","Clinically significant findings on exam or ultrasound\n","salpingitis, hydrosalpynx or evidence of ovarian cysts\n","hypersensitivity\n","Known hypersensitivity to any of the components of the solution\n","hypersensitivity\n","vaginal progesterone\n","excipients\n","components of the solution\n","Other protocol defined exclusion criteria could apply\n","Active\n","opioid dependence\n","Acute\n","chronic\n","pain\n","Acute or chronic\n","opioid treatment\n","Acute liver injury\n","liver aminotransferase concentrations\n",">5 times the upper limit of normal\n","liver aminotransferase concentrations >5 times the upper limit of normal\n","Health condition\n","considered unsafe for inclusion\n","at discretion of PI and/or attending physician\n","willingness to consent\n","Lack of\n","capacity or willingness to consent\n","alcohol dependence\n","pharmacotherapy\n","Currently\n","not including\n","treatment\n","acute alcohol withdrawal syndrome\n","Previous\n","significant\n","adverse reaction\n","naltrexone\n","diluent\n","naltrexone or diluent\n","Pregnant\n","nursing\n","not\n","birth control\n","effective methods\n","Prisoners\n","Office of Human Research Protection\n","at the time of enrollment\n","the time of enrollment\n","None\n","Skipping entity\n","Male\n","female\n","ages\n","18-65 years\n","Patients (or legal representative) willing and able to provide written Informed Consent Form\n","schizophrenia\n","bipolar disorder\n","Diagnostic and Statistical Manual of Mental Disorders- IV\n","Diagnostic and Statistical Manual of Mental Disorders- V\n","International Code of Disease criteria\n","schizophrenia or bipolar disorder,\n","Diagnostic and Statistical Manual of Mental Disorders- IV, Diagnostic and Statistical Manual of Mental Disorders- V or International Code of Disease criteria\n","agitation episode\n","within the 6 months prior to screening\n","screening\n","ADASUVE\n","CGI-I score\n","1 or 2\n","2 hours after administration of the inhalation)\n","administration of the inhalation)\n","free\n","respiratory disease\n","active\n","acute respiratory signs\n","wheezing\n","airways disease\n","active\n","asthma\n","chronic obstructive pulmonary disease\n","emphysema\n","asthma, chronic obstructive pulmonary disease or emphysema\n","acute respiratory signs/symptoms (e g , wheezing)\n","Requirement of family or other caregiver support at study investigator criteria (defined as a patient's relative or caregiver (male or female) = 80 year old, who spend = 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures\n","Availability of patient's medical records data about the previous treatment with ADASUVE® at hospital setting\n","If a female is of childbearing potential and sexually active (except if female is surgically sterile or post-menopausal with history of no menses for at least 24 months), patient must be non-lactating and non-pregnant (with a negative pregnancy test result at baseline visit) and have to agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study\n","HIV infection\n","CSF HIV RNA\n","Roche Amplicor assay\n","> 1,000 copies/ mL\n","antiretroviral therapy (ART\n"," Off antiretroviral therapy (ART\n","> 6 weeks before the\n","the\n","plans to\n","None\n","Skipping entity\n","for the study\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n"," Predicted adherence to the\n","4  Capable of providing informed\n"," > 18\n","None\n","Skipping entity\n","  6  CD4 cell\n",">150\n","be >250\n","   7  When available, subjects will be screened for stability of blood CD4 and HIV RNA\n","Inpatient\n","outpatient\n","age\n","8-19 years\n","Fluent in English;\n","participants must live with a parent, guardian, or caregiver\n","bipolar spectrum disorders\n","BSD\n","bipolar I\n","bipolar II\n","unspecified bipolar and related disorders\n","Disruptive Mood Dysregulation Disorder\n","DMDD\n","cyclothymic disorder\n","other specified bipolar and related disorders\n","mood disorder not otherwise specified\n","bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified\n","Body mass index\n",">85%ile\n","at least one\n","SGA\n","olanzapine\n","clozapine\n","risperidone\n","quetiapine\n","aripiprazole\n","ziprasidone\n","iloperidone\n","lurasidone\n","paliperidone\n","brexpiprazole\n","cariprazine\n","olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine\n","allergies\n","propofol\n","dexmedetomidine\n","fentanyl\n","eggs\n","egg products\n","soy\n","soy products\n","propofol, dexmedetomidine, fentanyl, eggs or egg products, or soy or soy products\n","heart rate\n","less than 50 beats/minute\n","AV heart block\n","grade 2\n","grade 2 or 3\n","Mean arterial pressure\n","less than 55 mmHg\n","fluid resuscitation\n","vasopressor\n","triglyceride level\n","> 400 mg/dl\n","adenocarcinoma\n","tumor\n","Central nervous system (CNS)\n","None\n","Skipping entity\n","CNS\n","  Gastric outlet\n","intestinal\n","of gastrointestinal\n","  Evidence\n","has bony\n","as the\n","evaluable\n","None\n","Skipping entity\n","of\n","than stomach\n","non-melanoma skin\n","or in situ carcinoma of the cervix\n","None\n","Skipping entity\n","for\n","non-melanoma skin cancer or in situ carcinoma of the cervix\n","  \n","or\n","None\n","Skipping entity\n","of childbearing\n",",\n","None\n","Skipping entity\n","not\n","Other serious\n","or medical\n","  Unstable cardiac\n","despite\n",", myocardial\n","within 6 months prior to\n","or psychiatric\n","None\n","Skipping entity\n","or\n","dementia or\n","neurologic or psychiatric\n","entry\n","None\n","Skipping entity\n","  Active\n","None\n","Skipping entity\n","impair the ability of the patient to\n","any other\n","the study\n","concomitant\n",",\n","therapy, or\n",", or\n","concomitant chemotherapy, hormonal therapy, or\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","concomitant\n","S-1\n","i  Warfarin,\n",": increase\n","ii  Increase blood\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","according to\n","of childbearing potential not employing adequate\n",": increase\n","tendency ii  Increase blood\n","medication; The following drugs cause drug\n","other\n",",\n","Other\n","Spanish speaking\n","Emergency Department\n","Aged\n","18-80\n",">4\n","emergency department visits\n","within 12 months\n","12-month periods\n","2 consecutive\n","incarcerated\n","institutionalized\n","incarcerated or institutionalized\n","extended by up to 6 months\n","Diagnostic and Statistical Manual version IV (DSM-IV) criteria\n","alcohol dependence\n","DSM-V criteria\n","alcohol use disorder\n","severe\n","≥2 days/week\n","heavy drinking\n",">4\n","drinks/day\n","informed consent\n","Capable of giving\n","infertile\n","women\n","intracytoplasmic sperm injection (\n","in Vitro and Embryo Transfer (FIVET)\n","Less than or equal to (<=) 1\n","previous failed embryo transfer\n","Eumenorrheic\n","normo-gonadotropic\n","women\n","Basal follicle-stimulating hormone (FSH)\n","<=12 International unit per liter (IU/L)\n","Anti-mullerian hormone (AMH)\n","greater than (>) 1 1 nanogram per milliliter (ng/mL)\n","number of antral follicles 2 millimeter (mm)\n","between 6 <= antral follicle count (AFC) <= 16\n","Follicles > 16 mm\n","between 5-14\n","at the triggering day\n","Body Mass Index (BMI)\n","between 18 <= BMI <= 27 kilogram per meter square (kg/m^2)\n","Indication for\n","Fresh Embryo transfer\n","ultrasound exam\n","Normal uterine cavity\n","no presence of\n","hydrosalpinx\n","no presence of hydrosalpinx\n","Assisted Reproductive Technique (ART)\n","oocyte maturation\n","human chorionic gonadotropin (HCG) triggering\n","Undergoing\n","Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering\n","Progesterone (P4) serum level\n","at the HCG triggering day\n","the HCG triggering day\n","<= 1 5 ng/mL\n","Day O/Randomization\n","Estradiol (E2)\n","<= 3000 picogram/milliliter (pg/mL)\n","the human chorionic gonadotropin (HCG) triggering day\n","at the human chorionic gonadotropin (HCG) triggering day\n","Day 0/Randomization\n","Subjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care\n","Other protocol defined inclusion criteria could apply\n","MET\n","1000 mg bid\n","at least 2 weeks in the past 3 months\n","not tolerate\n","MET\n","thyroid disease\n","unstable\n","diabetes mellitus\n","insulin\n","chronic renal failure\n","steroids\n","Fasting glucose\n","= 126 mg/dL\n","2\n","serum creatinine\n","=1 3 mg/dL\n","2\n","Pregnant or breast feeding\n","Children and caregivers who are unable to complete assessments for any reason\n","tetracycline\n","within 6 months\n","history\n","adverse reaction\n","minocycline\n","tetracycline\n","minocycline or another tetracycline\n","lumbar\n"," Enhanced\n","cerebral mass\n","predisposing to brain herniation or bleeding\n","predisposing\n","brain\n","bleeding\n","brain herniation or bleeding\n","None\n","Skipping entity\n","None\n","Skipping entity\n","documented or\n","documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding\n"," Enhanced risk from lumbar\n"," \n","None\n","Skipping entity\n","None\n","Skipping entity\n","during the\n"," Pregnancy or expectation of\n","opportunistic\n","None\n","Skipping entity\n","4  \n","neurological\n","or\n","5  ADC\n","None\n","Skipping entity\n","6  \n","< 10\n","   \n","or\n","above the normal\n","   7  BUN or\n","of\n","to reduce the metabolism of\n","   8  Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of\n","dementia\n","serious\n","unstable\n","serious and unstable\n","hepatic\n","renal\n","gastroenterologic\n","respiratory\n","cardiovascular\n","neurologic\n","endocrinologic\n","ischemic heart disease\n","congestive heart failure\n","stroke\n","transient ischemic attack\n","subarachnoidal bleeding\n","brain tumor\n","encephalopathy\n","meningitis\n","stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis\n","ischemic heart disease and congestive heart failure)\n","hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis\n","allergic reactions\n","loxapine\n","amoxapine\n","loxapine or amoxapine\n","Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded\n","Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device\n","Men\n","women\n","old\n","18-89 years\n","sepsis\n","within the previous 24 hours\n","mechanical ventilation\n","provide informed consent either personally or by an authorized representative\n","sensitivity\n","study medications\n","RA\n","intolerance\n","MTX\n","antiplatelet therapy\n","Current\n","anti-platelet therapy\n","Absolute indication for\n","Need for\n","chronic oral anticoagulant therapy\n","Severe hepatic impairment\n","ascites\n","coagulopathy\n","clinical signs of\n","ascites and/or clinical signs of coagulopathy\n","Renal failure\n","eGFR\n","<30\n","requiring\n","dialysis\n","eGFR <30 or requiring dialysis\n","bleeding diathesis\n","coagulation disorder\n","major bleeding\n","stroke\n","Active\n","Prior\n","prior\n","pathological bleeding\n","intracranial haemorrhage\n","History\n","Life expectancy\n","<12 months\n","based on investigator's judgement\n","bradycardic events\n","at risk of\n","sick sinus syndrome\n","third degree atrioventricular [AV)] block\n","permanent pacemaker\n","unless\n","sick sinus syndrome or second or third degree atrioventricular [AV)] block\n","Anemia\n","hematocrit\n","< 27%\n","hematocrit < 27%\n","Platelet count\n","< 100,000/ml\n","strong CYP 3A inhibitors\n","thrombocytopenia\n","neutropenia\n","History\n","thrombocytopenia or neutropenia\n","Pregnant\n","nursing\n","women\n","females\n","positive\n","pregnancy test\n","at screening\n","Pregnant or nursing women\n","females with a positive pregnancy test at screening\n","screening\n","Females\n","child bearing potential\n","acceptable\n","method of birth control\n","during study\n","prior to or during study\n","not\n","drug abuse\n","alcohol or drug abuse\n","inability of the patient to comply with study procedures and/or follow up\n","Concern for\n","uncontrolled\n","hypertension\n","uncontrolled\n","diabetes\n","creatinine\n","> 2,5 mg/dl\n","potassium\n","> 6 mg/dl\n","acute coronary syndrome\n","hypertrophic cardiomyopathy\n","1\n","2\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","GTC seizures\n","primary GTC\n","partial onset seizures\n","secondary generalization\n","primary GTC or partial onset seizures with secondary generalization\n","history\n","vEEG\n","None\n","Skipping entity\n","admitted to a\n","None\n","Skipping entity\n"," \n","the\n","an upper arm\n","is adequate for proper fit of the EMG\n","is adequate for proper fit of the EMG\n","(at least\n","of childbearing\n"," If\n"," If female and of childbearing\n","pregnancy\n","a\n","6  Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study\n","6  Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study\n","   7  Subject and/or Primary Caregiver must be competent to follow all study\n","   7  Subject and/or Primary Caregiver must be competent to follow all study\n","   8  Is able to read, speak, and understand\n","gestation\n","singleton fetus\n","Living\n","major fetal malformations\n","No\n","Cephalic presentation\n","No\n","uterine scar\n","fetal membranes\n","Intact\n","prostaglandin administration\n","Parkland protocol\n","cervical dilation\n","2 centimeters or less\n","internal os\n","indication\n","attempted\n","Parkland protocol\n","induction\n","induction or attempted induction of labor\n","substance abuse\n","preceding 12 months\n","alcohol or substance abuse\n","Women who are pregnant or breastfeeding\n","Women of childbearing potential (WOCP) who are not using at least one method of contraception\n","renal impairment\n","severe\n","CLcr\n","= 29 mL/min\n","eGFR\n","= 29 mL/min/1 73 m2\n","CLcr = 29 mL/min, or eGFR = 29 mL/min/1 73 m2\n","hepatic impairment\n","severe\n","moderate\n","moderate or severe\n","Child-Pugh classes\n","B\n","C\n","B or C\n","bladder outlet obstruction\n","BOO\n","mirabegron\n","risk of urinary retention\n","Patients treated with drugs metabolized by the CYP2D6 pathway\n","systolic blood pressure\n","supine\n","SBP\n","= 180 mm Hg\n","diastolic blood pressure\n","DBP\n","= 110 mm Hg\n","cardiac arrhythmia\n","uncontrolled\n","unstable angina\n","congestive heart failure\n","NYHA Class\n","3\n","4\n","3 or 4\n","myocardial infarction\n","preceding 2 years\n","cancer\n","preceding 2 years\n","other\n","cervical cancer in situ\n","basal cell carcinoma\n","non-metastatic\n","squamous cell or basal cell carcinoma, or cervical cancer in situ\n","successfully treated\n","major urological procedure\n","preceding 90 days\n","major surgical procedure\n","preceding 30 days\n","mirabegron\n","within 60 days prior to the baseline visit\n","baseline visit\n","antimuscarinic agents\n","OAB symptoms\n","within the 60 days preceding the baseline visit\n","baseline visit\n","willingness to not use antimuscarinic agents for the duration of the study\n","Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2)\n","Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study\n","Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures\n","decompensated\n","liver disease\n","Childs\n","B-C\n","decompensated liver disease\n","Childs B-C\n","hepato-cellular carcinoma\n","pre-existing\n","severe\n","depression\n","psychiatric disease\n","other\n","cardiac disease\n","significant\n","significant\n","renal disease\n","seizure disorders\n","severe\n","retinopathy\n","severe depression or other psychiatric disease\n","telbivudine\n","antiviral therapy\n","more than one\n","NA\n","in the past\n","interferon\n","peginterferon\n","treatment\n","in the past\n","interferon or peginterferon\n","antiviral therapy\n","systemic anti-viral\n","immuno-modulatory treatment\n","supraphysiologic doses\n","steroids\n","radiation\n","supraphysiologic doses of steroids and radiation\n","antiviral therapy for any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment\n","within the past 6 months\n","Positive\n","at screening\n","expected to need\n","systemic antiviral therapy\n","at any time during their participation in the study\n","their participation in the study\n","acyclovir\n","<=7 days\n","herpetic lesions\n","more than 1 month prior to the first administration of test drug\n","the first administration of test drug\n","not excluded\n","Exception\n","Serum total bilirubin\n","> 3 times the upper limit of normal\n","at screening\n","bleeding\n","esophageal varices\n","other\n","conditions consistent with decompensated liver disease\n","medical condition\n","chronic liver disease\n","other than\n","HBV\n","other than HBV\n","hemochromatosis\n","autoimmune hepatitis\n","metabolic liver diseases\n","Wilson's\n","alpha1-antitrypsin deficiency\n","alcoholic liver disease\n","toxin exposures\n","thalassemia\n","Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia\n","hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia\n","Women\n","pregnancy\n","ongoing\n","breast feeding\n","Neutrophil count\n","<1500 cells/mm3\n","platelet count\n","<90,000 cells/mm3\n","at screening\n","Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3\n","Hemoglobin\n","< 11 5 g/dL\n","females\n","< 12 5 g/dL\n","men\n","at screening\n","< 11 5 g/dL for females and < 12 5 g/dL for men\n","Serum creatinine level\n",">120 umol/ml\n","men\n",">105 umol/ml\n","women\n","at screening\n",">120 umol/ml for men and >105 umol/ml for women\n","psychiatric disease\n","severe\n","depression\n","Severe\n","psychiatric disease\n","major depression\n","psychosis\n","treatment\n","antidepressant medication\n","major tranquilizer\n","therapeutic doses\n","depression\n","psychosis\n","for at least 3 months\n","suicidal attempt\n","hospitalization\n","psychiatric disease\n","disability\n","psychiatric disease\n","antidepressant medication or major tranquilizer\n","major depression or psychosis, a period of treatment with an antidepressant medication or major tranquilizer at therapeutic doses for depression or psychosis for at least 3 months, a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease\n","Severe psychiatric disease\n","severe psychiatric disease, especially depression\n","inflammatory bowel disease\n","immunologically mediated disease\n","idiopathic thrombocytopenic purpura\n","lupus erythematosus\n","autoimmune hemolytic anemia\n","scleroderma\n","severe\n","psoriasis\n","rheumatoid arthritis\n","inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis\n","chronic pulmonary disease\n","functional limitation\n","Severe\n","cardiac disease\n","NYHA\n","Functional Class III or IV\n","myocardial infarction\n","within 6 months\n","ventricular tachyarrhythmias\n","ongoing\n","treatment\n","unstable angina\n","other\n","significant\n","cardiovascular diseases\n","Severe cardiac disease\n","NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases\n","severe\n","seizure disorder\n","anticonvulsant\n","current\n","active\n","suspected\n","cancer\n","active or suspected\n","malignancy\n","risk of recurrence\n",">=20% within 2 years\n","lesion\n","suspicious\n","hepatic malignancy\n","screening imaging study\n","likelihood of carcinoma\n","<=10%\n","lesion suspicious of hepatic malignancy on a screening imaging study\n","systemic\n","immunomodulatory treatment\n","radiation\n","systemic\n","corticosteroids\n","anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids)\n","<=6 months prior to the first dose of study drug\n","the first dose of study drug\n","expectation\n","treatment\n","will be needed\n","at any time during the study\n","Major organ transplantation\n","Thyroid disease\n","thyroid function\n","poorly controlled\n","on prescribed medications\n","abnormal\n","thyroid stimulating hormone\n","T4 concentrations\n","abnormal thyroid stimulating hormone or T4 concentrations\n","abnormal thyroid stimulating hormone or T4 concentrations\n","antibodies to thyroid peroxidase\n","elevation\n","clinical manifestations of thyroid disease\n","severe\n","retinopathy\n","CMV retinitis\n","macula degeneration\n","CMV retinitis, macula degeneration\n","severe retinopathy\n","clinically relevant\n","ophthalmological disorder\n","diabetes mellitus\n","hypertension\n","diabetes mellitus or hypertension\n","Inability or unwillingness to provide informed consent or abide by the requirements of the study\n","History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study\n","alpha-fetoprotein\n",">100 ng/mL\n","at least the previous 3 months\n","the previous 3 months\n","stability\n","less than 10%\n","increase\n","less than 10% increase\n","unless\n","alcohol abuse\n","20g/day\n","30g/day\n","men\n","women\n","20g/day for women & 30g/day for men\n","Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening\n","hypersensitivity\n","interferon\n","Autism\n","Pervasive Developmental Disorder not otherwise specified\n","PDD-NOS\n","given by a child neurologist\n","Age\n","10-18 years\n","A signed parental consent form\n","anaemia\n","males\n","Hb\n","<130 g/L\n","females\n","<120 g/L\n","males Hb <130 g/L, females <120 g/L\n","elective\n","cardiac surgery\n","available to receive\n","trial drug\n","1- 10 weeks prior to surgery\n","surgery\n","surgery\n","Adult\n","male\n","female\n","emergency endotracheal intubation\n","Abnormal karyotype\n","abdominal\n","None\n","Skipping entity\n","pelvic or abdominal\n","surgical\n","ovarian\n","  \n","  Chronic\n","  Chronic\n",": renal, liver, cardiac,\n","Age\n","greater than 18\n","None\n","Skipping entity\n","low probability(by surgeon estimate) of conversion to open\n","low probability(by surgeon estimate) of conversion to open\n","Planned thoracoscopy with low probability(by surgeon estimate) of conversion to open\n","low probability(by surgeon estimate) of conversion to open\n","Healthy\n","Male\n",">7\n","Metabolic Equivalents\n","Written informed consent\n","Chronic pain syndrome\n","Drug abuse\n","Alcohol abuse\n","Suspicion\n","neurologic dysfunction\n","tested sites\n","Ongoing\n","treatment\n","antidepressants\n","Ongoing\n","treatment\n","analgesics\n","Pretreatment\n","CYP3A inducers\n","CYP3A inducers or inhibitors\n","allergy\n","tested drugs\n","Elevated eye pressure\n","Obstructive uropathy\n","Heart disease\n","Pulmonary disease\n","Neurological disease\n","Psychiatric illness\n","-Patients residing in the following clinical states wit!\n","be considered: A\n","PSA\n","Rising\n","history of\n","localized disease\n","radiation\n","surgery\n","definitive\n","radiation or surgery\n","progression of disease\n","biochemically\n","radiographically evident\n","disease\n"," Non-\n","None\n","Skipping entity\n","radiographic\n","None\n","Skipping entity\n","metastatic\n","at the time of\n","after treatment for localized\n","None\n","Skipping entity\n","localized\n","treatment for localized\n","the time of\n","at the time of diagnosis or after treatment for localized\n"," Non-castrate\n","newly\n","progressing disease in\n"," Biochemical\n","Minimal % increase in range of\n","50\n","Minimal Baseline PSA\n","(ng/ml):\n","minimum no  of\n","None\n","Skipping entity\n","None\n","Skipping entity\n",">2\n","minimum no  of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50\n","disease or progressing disease in bone or in soft\n","prostate\n","None\n","Skipping entity\n","None\n","Skipping entity\n","histologically\n","level of serum\n","above the lower limit of\n","   Karnofskcy performance status (\n",") >\n","have\n","organ\n","have adequate organ\n",":\n","  WBC >_\n","/mm3, platelet\n","count >_\n","mm3    \n","<2\n","/dl\n","SGOT <3 0 X the upper limit of\n","   \n","<_1\n","/dl or creatinine\n",">_\n","/min\n","   Prior\n","therapy\n","as:   1  Neoadjuvant\n","treatment prior to radiation therapy or radical\n","prior to\n","or radical\n","prior to radiation therapy or radical\n","that the total duration\n","exposure does not exceed\n","   2\n","cycle of\n","up to a\n","None\n","Skipping entity\n","must be at\n","18\n","must have signed an informed\n","Untreated\n","psychiatric\n","psychiatric\n","Medical or psychiatric conditions comprising informed\n","Medical or psychiatric conditions comprising informed\n","Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the\n","Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the\n","   \n","within 4 weeks of trial\n","of trial\n","autoimmune\n","   \n","systemic\n","in past 2\n","of\n","  Chronic\n","immunosuppressant\n","immunosuppressant\n","of\n","None\n","Skipping entity\n","None\n","Skipping entity\n","   Any evidence of clinical\n","allergy\n","latex\n","fetal status\n","non-reassuring\n","HIV\n","herpes\n","active\n","uterine scar\n","Contraindication\n","prostaglandins\n","Parkland protocol\n","Contraindication\n","vaginal delivery\n","1\n","2\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","generalized seizures\n","history\n","not\n","GTC\n","None\n","Skipping entity\n","within the last\n","anti-epileptic\n","reduction of anti-epileptic\n","during their hospital\n","hospital\n","None\n","Skipping entity\n"," Intracranial EEG\n","'s upper arm\n","adequate for proper fit of the EMG\n","None\n","Skipping entity\n","adequate for proper fit of the EMG\n","(less than\n","None\n","Skipping entity\n","5  \n","6  Subject/Caregiver is unable to provide\n","6  Subject/Caregiver is unable to provide\n","heart failure\n","NYHA\n","II-IV\n","treatment\n","previous\n","diuretics\n","None\n","Skipping entity\n","years\n","RA\n","MTX\n","stable doses\n","10 to 25 mg weekly\n","for at least 12 weeks\n","DAS28\n","3 2 or higher\n","(The level of disease activity is considered to be low if the DAS28 is 3 2 or less) (Prevoo et al , 1995)\n","OA\n","osteoarthritis\n","made by physician\n","MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3 2 or higher (The level of disease activity is considered to be low if the DAS28 is 3 2 or less) (Prevoo et al , 1995)\n","osteoarthritis made by physician\n","Pregnancy\n","hypersensitivity\n","study drug\n","ferric carboxymaltose\n","haemoglobinopathy\n","thalassaemia\n","suspected\n","Known\n","Known or suspected\n","haemoglobinopathy/thalassaemia\n","Bone marrow disease\n","Haemochromatosis\n","Renal dialysis\n","Erythropoietin\n","IV iron\n","in the previous 4 weeks\n","Erythropoietin or IV iron\n","infectious disease\n","underlying\n","chromosomal abnormality\n","metabolic disorder\n","disorder\n","brain\n","tuberous sclerosis\n","cytomegalovirus infection\n","fetal\n","birth asphyxia\n","major head injury\n","chronic use\n","non-steroidal anti-inflammatory drugs\n","NSAID\n","brain damage\n","Epilepsy\n","Electro-cardiogram\n","ECG\n","Abnormal\n","EEG\n","Epileptiform\n","psychostimulants\n","anti-depressants\n","neuroleptics\n","anti-convulsive agents\n","within the past month\n","psychostimulants, anti-depressants, neuroleptics or anti-convulsive agents\n","Lack of cooperation in the screening phase\n","Male\n","female\n",">= 18 and < 70 years\n","age\n","HBeAg\n","Positive\n","before starting NA treatment\n","starting NA treatment\n","lamivudine\n","adefovir\n","entecavir\n","tenofovir\n","single\n","NA\n","Treated\n","lamivudine, adefovir, entecavir or tenofovir\n","for 6 months to 5 years\n","HBeAg\n","seroconversion\n","HBeAg\n","ant-HBe\n","negative\n","negative\n","HBeAg negative and ant-HBe negative\n","undetectable\n","HBV DNA\n","PCR based assay\n","NA\n","treatment\n","Negative\n","serum pregnancy test\n","urine or serum pregnancy test\n","women\n","childbearing potential\n","women of childbearing potential\n","within the 24-hour period prior to the first dose of test drug\n","the first dose of test drug\n","Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completion\n","Aged\n","25-80\n","Subjects older than 80 will be allowed at the discretion of the PI\n","Ambulatory\n","defined as able to ambulate at least 10 meters, with or without assistance\n","PD\n","United Kingdom Brain Bank diagnostic criteria\n","micturitions\n","urgency episodes\n","MoCA score\n","between 19 and 28\n","cognitive enhancers\n","donepezil\n","rivastigmine\n","memantine\n","galantamine\n","MoCA score\n","between 19 and 29\n","donepezil, rivastigmine, memantine, galantamine\n","cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29\n","Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care\n","Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent\n","Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks\n","antiparkinson's medications\n","at least 30 days prior to screening\n","screening\n","cognitive enhancers\n","donepezil\n","rivastigmine\n","memantine\n","galantamine\n","donepezil, rivastigmine, memantine, galantamine\n","stable dose\n","at least 30 days prior to screening\n","screening\n","Children\n","<18 years\n","old\n","<18 years old\n","Women\n","pregnant\n","randomized\n","previously\n","endotracheal intubation\n","require\n","sedative medication\n","without\n","full cardiac arrest\n","allergy\n","ketamine\n","etomidate\n","ketamine or etomidate\n","Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial\n","cardiac disease\n","New York Heart Association\n","Class III/\n","significant\n","debilitating puhnonary disease\n","severe\n","None\n","Skipping entity\n","Uncontrolled\n","Anticipated\n","less than 3\n","or\n","  \n","or\n","to comply with the treatment\n",",\n","or research\n","to comply with the treatment protocol, follow-up, or research\n","  Inability or\n","NSCLC\n","PD-L1 status\n","Biopsy\n","within 70 days of first treatment\n","first treatment with pembrolizumab\n","pembrolizumab\n","ECOG performance\n","None\n","Skipping entity\n","Life\n","to Response Evaluation Criteria in Solid Tumours (RECIST)\n","   Uni-dimensionally\n","None\n","Skipping entity\n","None\n","Skipping entity\n","1   Computerised Tomography (CT) scan of chest and\n","within 28 days of starting\n","of starting\n","None\n","Skipping entity\n",":   Platelet\n","count ≥100 x\n","/L    \n","≥1 5\n","/L    \n","None\n","Skipping entity\n","   Adequate haematological\n","9g/dL    Adequate hepatic\n",":   Serum\n","bilirubin ≤1 5 x upper limit of\n","(ULN)    Serum\n","None\n","Skipping entity\n","function:\n","clearance <1\n","5 times\n","with\n","None\n","Skipping entity\n","   Adequate\n","5 x ULN\n","function: Creatinine clearance <1 5 times ULN concurrent with creatinine\n","50 ml/min    Provision of signed and dated, written informed consent prior to any study specific procedures, sampling\n","50 ml/min    Provision of signed and dated, written informed consent prior to any study specific procedures, sampling\n","Women\n","POI\n","aged\n","less than 40 years\n","amenorrhea\n","at least 4 month\n","FSH level\n","above 25 IU/L\n","repeated twice\n",">4 weeks apart\n","aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart)\n","Age\n","less than 18\n","Clinical or laboratory evidence of systemic\n","None\n","Skipping entity\n","urine HCG\n","None\n","Skipping entity\n","None\n","Skipping entity\n",", non-malignant\n",",\n","  \n","  Malignant\n","systemic\n","in the last 6\n","to\n",", morphine\n","or\n","None\n","Skipping entity\n","to oxycodone, morphine sulfate or\n","  Contraindication to peripheral nerve\n",":   1  patient\n","  2  active infection at site of\n","block   3  documented allergy to any local or general anesthetic\n","None\n","Skipping entity\n","  4  \n","(\n","time >\n","None\n","Skipping entity\n","None\n","Skipping entity\n","( prothrombin time >15\n","-existing\n","5   5  \n","and medical conditions or deformities which would compromise block or\n","  Planned\n","safety   Planned\n","or\n","of high\n","None\n","Skipping entity\n","of high dose\n","use\n","None\n","Skipping entity\n","use\n","None\n","Skipping entity\n","None\n","Skipping entity\n","(Cordarone)\n","None\n","Skipping entity\n","None\n","Skipping entity\n","significant\n","issues\n","treatment with\n","None\n","Skipping entity\n","  Patients with\n","  Patients with clinically significant mental health issues\n","medications    Patients\n","with\n","  \n","None\n","Skipping entity\n","antibiotics within one\n","of registration   Participation in other clinical trials that may\n","age\n","8- 18 years\n","2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure\n","3) American Society of Anesthesiology Status I-III\n","minimally invasive pectus excavatum repair\n","Nuss procedure\n","American Society of Anesthesiology Status\n","I-III\n","coma\n","convulsion\n","paralysis\n","intracranial hemorrhage\n","central nervous system\n","leukemia\n","at diagnosis\n","intracranial hemorrhage or central nervous system leukemia\n","coma, convulsion or paralysis\n","Women\n","singleton pregnancy\n","preterm labor\n","midtrimester miscarriage\n","previous\n","pregnancy\n","previous pregnancy\n","preterm labor and/or midtrimester miscarriage\n","Cervical length\n","15-25 mm\n","transvaginal sonography (TVS)\n","16-24 weeks\n","gestation\n","at 16-24 weeks of gestation\n","16-24 weeks of gestation\n","Ph (BCR/ABL)\n","positive\n","de novo\n","< 55 years\n","old\n","(it is advisable to include patients over 55 years LAL07OPH protocol)\n","Performance status\n","0-2\n","functional impairment of organs\n","(Appendix B) may include patients with performance status > 2 attributable to LAL\n","without\n","total bilirubin\n","AST\n","ALT\n","alfa-GT\n","alkaline phosphatase\n","less than 3 times the upper limit of normal\n","total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase\n","total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal\n","without functional impairment of organs\n","serum creatinine\n","< 2 mg/dL\n","clearance creatinine\n","> 30 ml/min\n","(except renal function attributable to LAL)\n","cardiac function\n","normal\n","ventricular EF\n","> 50%\n","absence of\n","severe chronic respiratory disease\n","cardiac function (Appendix B) normal\n","ventricular EF > 50%\n","In the event that alterations are secondary to the disease is at the discretion of the investigator to determine if the patient can be included in the trial\n","total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease\n","allergy\n","drugs used\n","coagulopathy\n","wound\n","infection\n","puncture site\n","wound or infection\n","consent of parents\n","failure to gain\n","failure to gain consent of parents\n","major\n","illness\n","Refusal\n","epidural catheter\n","Pregnancy\n","Bleeding\n","History\n","Inability to understand how to use the PCA device\n","Medication\n","interfering with blood coagulation\n","allergic\n","local anesthetics\n","1) Refusal of epidural catheter\n","2) Pregnancy\n","3) Bleeding History\n","4) Inability to understand how to use the PCA device\n","5) Medication interfering with blood coagulation\n","6) Patients allergic to local anesthetics\n","7) Patient refusal to participate in study\n","8) Developmental delay\n","Patient refusal to participate in study\n","Developmental delay\n","Age\n","< 20\n","> 35 years\n","< 20 or > 35 years\n","Congenital uterine malformation\n","Multifetal pregnancy\n","chromosomal abnormality\n","fetal structural\n","major\n","fetal structural or chromosomal abnormality\n","allergy\n","contraindication\n","relative\n","absolute\n","progesterone therapy\n","relative or absolute\n","allergy or contraindication\n","contraindication\n","cervical cerclage\n","Medical conditions\n","complicating pregnancy\n","Vaginal bleeding\n","less than 16 years\n","old\n","PML-RARa\n","positive\n","acute promyelocytic leukemia\n","ASA\n","I or II\n","other variety\n","LAL\n","history\n","coronary artery disease\n","hypertensive heart disease\n","coronary artery disease, valvular or hypertensive heart disease\n","chronic liver disease\n","chronic respiratory failure\n","Renal failure\n","LAL\n","not\n","due to\n","positive\n","HIV status\n","No\n","serious\n","neurological abnormalities\n","due to\n","LAL\n","Impact on overall severe (grade 3 or 4 of the WHO scale) not attributable to the LAL\n","Pregnant\n","breastfeeding\n","blast crisis\n","CML\n","Diabetes mellitus type 1\n","renal insufficiency\n","III-V °\n","Cirrhosis hepatis\n","Child\n","B or higher\n","Child B or higher\n","Chronic\n","alcohol abuse\n","rheumatic disease\n","RA\n","SpA\n","SLE\n","RA, SpA, SLE\n","Malignancies\n","<5 years\n","Eating Disorder\n","anorexia nervosa\n","bulimia\n","anorexia nervosa, bulimia\n","bone-specific pretreatment\n","DMAB\n","TPTD\n","SERMs\n","strontium ranelate\n","Bisphosphonate treatment is allowed\n","DMAB, TPTD, strontium ranelate, SERMs\n","Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4 0 (except clinically insignificant toxicities such as alopecia)\n","Subjects receiving any other investigational agents\n","tumor lysis syndrome (\n","central nervous system (CNS)\n","meningeal\n","as\n","CNS parenchymal\n","as symptomatic meningeal lymphoma or known CNS parenchymal\n","allergic\n","of\n","to compounds of similar chemical or biologic composition to\n","to compounds of similar chemical or biologic composition to rituximab or other agents used in this\n","to compounds of similar chemical or biologic composition to rituximab or other agents used in this\n","   Subjects with uncontrolled intercurrent\n","    HIV-\n","on combination antiretroviral\n"," Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when\n"," Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when\n"," HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV\n","for hepatitis B\n","(HBV), hepatitis B surface antigen\n","), or hepatitis C (HCV)\n","of\n","for HCV\n","who are\n","None\n","Skipping entity\n","must be\n","who are positive for HCV\n","HCV by polymerase chain\n","or prior HBV\n","positive total hepatitis B core\n","as\n","None\n","Skipping entity\n","] and\n","None\n","Skipping entity\n","DNA is\n","as positive total hepatitis B core antibody [HBcAb] and\n","HBsAg) may be\n"," These patients must be willing to undergo monthly DNA\n","None\n","Skipping entity\n","who\n","or\n","  \n","or other condition that precludes enteral route of\n","or other condition that precludes enteral route of\n","  \n","None\n","Skipping entity\n","radiation within 3 weeks of the first scheduled\n","3 weeks of the first scheduled\n","treatment    \n","than 2-year\n","from another\n","free\n","(other than squamous or basal cell\n","of the skin, \"in-situ\" carcinoma\n","or breast, superficial\n","treated localized\n","with normal prostate specific antigen\n","None\n","Skipping entity\n","(other than squamous or basal cell carcinoma of the skin, \"in-situ\" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen\n","all anti-\n","for another\n","None\n","Skipping entity\n","malignancy more than\n","prior\n","to screening\n","of relapse\n",", other than\n","surgery,\n","of high dose systemic\n","i e ,\n","of prednisone higher\n","chronic\n","2 weeks    \n","2 weeks    \n","None\n","Skipping entity\n","(i e , doses of prednisone higher\n",")  \n","treatment with\n","None\n","Skipping entity\n","or equivalent\n","allergy to both xanthine\n","inhibitors\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","is prohibited\n","with low-\n","heparin\n"," enoxaparin) or direct\n","None\n","Skipping entity\n","not allowed\n","days prior to the first\n","drug and\n","drug and during\n","administration: Strong\n","not\n","to\n","ketoconazole,\n","clarithromycin or\n","not\n","to\n","not limited to\n","not limited to fluconazole, ketoconazole,\n","not allowed from 7 days prior to the first dose of study drug and during\n","administration: Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to\n","   Receipt of\n","-virus vaccines\n","28 days prior to the initiation\n","study\n","or need for\n","-virus vaccines\n","at any time\n","study\n","study treatment    Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be\n","study treatment    Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be\n","   \n","None\n","Skipping entity\n","as\n","cautionary    \n","inducers such as\n","and\n","and\n","substrates such\n","None\n","Skipping entity\n","None\n","Skipping entity\n","(\n",") by\n","None\n","Skipping entity\n","recommended to\n","None\n","Skipping entity\n","substrates with a\n","by venetoclax  It is recommended to exclude CYP2C9 substrates with a narrow therapeutic\n"," In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive\n","None\n","Skipping entity\n","None\n","Skipping entity\n","anti-TNF agent\n","DMARD\n","dose increase\n","anti-TNF agent or DMARD\n","anti-TNF agent\n","DMARD\n","change\n","anti-TNF agent or DMARD\n","in the last 6 months\n","in the last 6 months\n","golimumab\n","certolizumab\n","greater than 10 mg\n","prednisone\n","daily\n","in the last 6 months\n","greater than 5 mg\n","prednisone\n","daily\n","in the last 3 months\n","intramuscular\n","intravenous\n","corticosteroids\n","in the last 6 months\n","RA\n","intramuscular or intravenous\n","anakinra\n","abatacept\n","tocilizumab\n","in the last 6 months\n","anakinra, abatacept, or tocilizumab\n","rituximab\n","in the last 12 months\n","investigational\n","RA drug\n","in the last 6 months\n","Pregnant\n","lactating\n","women\n","pregnancy\n","Absence of\n","clinical remission\n","for the last 6 months\n","Unwilling\n","discontinue\n","anti-TNF agent\n","Absence of\n","negative\n","tuberculin skin test\n","negative\n","QuantiFERON-TB Gold test\n","latent\n","tuberculosis\n","treatment\n","prior to starting treatment with the anti-TNF agent\n","starting treatment with the anti-TNF agent\n","treatment with the anti-TNF agent\n","anti-TNF agent\n","solid malignancy\n","non-melanoma skin cancer\n","within the past 5 years\n","melanoma\n","hematologic\n","lymphoproliferative malignancy\n","solid malignancy or non-melanoma skin cancer\n","cancer screening\n","age-appropriate\n","at the time of randomization\n","the time of randomization\n","hepatitis B serologies\n","negative\n","Absence of\n","treatment\n","chronic hepatitis B\n","absence of\n","completion of\n","suppressive antiviral treatment\n","absence\n","Unable to provide informed consent\n","Anticipate not being available or able to comply with the schedule of study visits\n","Contraindications\n","empagliflozin\n","Sitagliptin\n","empagliflozin, Sitagliptin\n","DPP4 inhibitors\n","Sodium-glucose cotransporter-2(SGLT2) inhibitors\n","within the previous 4 weeks\n","DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors\n","Insulin\n","diabetes\n","Poor glucose control\n","None\n","Skipping entity\n","%\n","HbA1C>10 %\n","Acute coronary syndrome\n","Stent\n","placement\n","within the previous 6 months\n","within the previous 6 months\n","coronary artery bypass graft surgery\n","Previous\n","revascularization\n","within 6 months\n","Planned\n","Heart failure\n","loop diuretics\n","left ventricular hypertrophy\n","Severe\n","left ventricular septal wall thickness\n","> 13mm\n","Severe left ventricular hypertrophy\n","left ventricular septal wall thickness > 13mm\n","Significant\n","renal disease\n","creatinine clearance\n","< 30 ml/min\n","Significant renal disease\n","creatinine clearance of < 30 ml/min\n","Hepatic disease\n","biliary tract obstruction\n","hepatic enzyme elevation\n","significant\n","alanine transaminase\n","Aspartate Aminotransferase\n","> 3 times upper limit of normal\n","alanine transaminase or Aspartate Aminotransferase\n","alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal\n","Radiopaque material\n","chest wall\n","adenosine stress test\n","Contraindication\n","Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study\n","pregnant\n","breast-feeding\n","child-bearing potential\n","Expected life expectancy\n","< 1 year\n","Unwillingness or inability to comply with the procedures described in this protocol\n","American Society of Anesthesiologist physical status\n","1-3\n","elective\n","Scheduled for\n","video-assisted thoracic surgery\n","patient-controlled analgesia device\n","PCA\n","Age\n","= 18 years\n","able to give written informed consent\n","Active\n","chronic\n","central serous chorioretinopathy (cCSC)\n","Subjective visual loss\n","> 6 weeks\n","interpreted as onset of active disease;\n","Foveal subretinal fluid (SRF)\n","optical coherence tomography (OCT)\n","at Baseline Examination\n","Baseline Examination\n","=1\n","ill-defined\n","hyperfluorescent leakage areas\n","fluorescein angiography (FA)\n","retinal pigment epithelial window defect(s)\n","that are compatible with cCSC\n","Hyperfluorescent areas\n","indocyanine green angiography (ICGA)\n","Postmenopausal\n","women\n","Age\n","60-80 years\n","T-score\n","DXA\n","according to DXA\n","<-2 5\n","indication for\n","osteoporosis therapy\n","osteoporosis\n","international guidelines\n","Men\n","women\n","at least 19 years\n","age\n","Type 2 diabetes mellitus\n","coronary artery disease\n","Stable\n","Global myocardial perfusion reserve (MPR) index\n","< 2 5\n","informed, written consent\n","Age\n","greater than or equal to 18 years\n","RA\n","1987 revised American College of Rheumatology criteria\n","sustained clinical remission\n","for the last 6 months\n","etanercept\n","infliximab\n","adalimumab\n","greater than or equal to 1\n","DMARD\n","methotrexate\n","hydroxychloroquine\n","sulfasalazine\n","leflunomide\n","minocycline\n","cyclosporine\n","azathioprine\n","gold\n","penicillamine\n","methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine\n","DAS28\n","less than 2 6\n","over the preceding 6 months\n","at least one\n","visit\n","visit\n","on each visit\n","2-4 months before enrollment\n","None\n","Skipping entity\n","Histological\n","confirmation\n","B-cell lymphoma\n","large\n","diffuse\n","rituximab and anthracycline-containing systemic treatment regimen\n","R-CHOP\n","rituximab\n","cyclophosphamide\n","doxorubicin\n","vincristine\n","prednisone\n","rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone\n","R-EPOCH\n","rituximab\n","etoposide phosphate\n","prednisone\n","vincristine sulfate\n","cyclophosphamide\n","doxorubicin hydrochloride\n","rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride\n","R-HyperCVAD\n","rituximab\n","cyclophosphamide\n","vincristine sulfate\n","doxorubicin hydrochloride\n","dexamethasone\n","rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone\n","rituximab\n","anthracycline\n","R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc\n","after\n","prior rituximab and anthracycline-containing systemic treatment regimen\n","no more than\n","None\n","Skipping entity\n","systemic therapies for\n","None\n","Skipping entity\n"," \n","conventional\n"," \n","None\n","Skipping entity\n","(\n","Vincristine\n","None\n","Skipping entity\n","(Cyclophosphamide, Vincristine Sulfate,\n","None\n","Skipping entity\n","non-Hodgkin's lymphoma (NHL\n","None\n","Skipping entity\n","None\n","Skipping entity\n"," bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or\n","None\n","Skipping entity\n","/extended-\n","maintenance/extended-\n","Eastern Cooperative Oncology Group (ECOG) Performance\n","≤\n","  Subjects must have normal organ and marrow function as defined\n",":   \n","≥ 8 0\n","dl   Absolute neutrophil\n","≥\n","mcL   Platelet\n","count ≥\n","/mcL   Total\n","≤ 1 5 X the upper limit of\n","of impaired bilirubin\n","as\n","≤ 1 5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be\n","ULN    Aspartate transaminase (AST\n","(SGOT) ≤ 2 5 X\n","ULN   Alanine transaminase (\n",") (SGPT) ≤ 2 5 X\n","ULN   International normalized\n","(INR)\n","calculated serum\n","clearance\n","/min using Cockcroft-Gault\n","based on 24-hour urine\n","performed within 7\n","prior\n","/min using Cockcroft-Gault calculation or based on 24-hour urine\n","   Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological\n","as\n",":   \n","None\n","Skipping entity\n",",\n","None\n","Skipping entity\n",",\n","None\n","Skipping entity\n","who\n","for HBsAg\n","None\n","Skipping entity\n","with\n","None\n","Skipping entity\n",", but\n","should have a\n","ineligible   Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility\n","as\n","  If HBV\n","as follow:   If HBV DNA is positive, the\n","None\n","Skipping entity\n","   If\n","be included but must undergo HBV DNA PCR testing monthly x 3 months beginning from the\n","of treatment   Subjects must have the ability to understand and the willingness to sign a written\n","document    For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab,\n","is longer    A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of\n","and/or uterus)    For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating\n","and/or uterus)    For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating\n","and/or uterus)    For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating\n",", as defined below:   With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the\n","dose of rituximab  Men must refrain from donating sperm\n","this same period    With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to\n","morphine\n","allergy\n","History\n","bupivacaine\n","allergy\n","History\n","Contraindication\n","ketamine\n","ketamine infusion\n","Contraindication\n","thoracic\n","paravertebral block\n","postoperative\n","positive pressure ventilation\n","Anticipated\n","postoperative positive pressure ventilation\n","Body mass index\n","more than 35\n","psychiatric disorder\n","active\n","CSC\n","treatments\n","previous\n","Previous\n","mineralocorticoid receptor antagonists\n","cCSC\n","other diseases\n","cCSC or for other diseases\n","corticosteroids\n","Current\n","topical\n","systemic\n","topical or systemic\n","corticosteroid use\n","within 3 months before possible start of trial treatment\n","possible start of trial treatment\n","corticosteroid treatment\n","within the first 2 years from the start of the trial period\n","the first 2 years from the start of the trial period\n","anticipated\n","Evidence of another diagnosis that can explain serous SRF or visual loss;\n","Best-corrected visual acuity\n","< 20/200\n","Profound\n","chorioretinal atrophy\n","central macular area\n","ophthalmoscopy\n","OCT\n","ophthalmoscopy and OCT\n","Myopia\n","> 6D\n","Visual loss\n","serous detachment\n","OCT\n","< 6 weeks\n","Visual loss and/or serous detachment\n","Continuous\n","progressive\n","visual loss\n","Continuous and/or progressive\n","> 18 months\n","serous detachment\n","OCT\n","> 18 months\n","ICGA\n","hyperfluorescence\n","No\n","Intraretinal edema\n","OCT\n","Contraindications\n","FA\n","ICGA\n","FA or ICGA\n","Contraindications\n","photodynamic treatment\n","pregnancy\n","porphyria\n","severely\n","disturbed liver function\n","pregnancy, porphyria, severely disturbed liver function\n","Contraindications for photodynamic treatment\n","Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening\n","contraindications\n","eplerenone\n","hyperkalemia\n","abnormal renal clearance\n","renal clearance\n","abnormal\n","severe hepatic insufficiency\n","Child-Pugh\n","C\n","type 2 diabetes mellitus\n","microalbuminuria\n","type 2 diabetes mellitus with microalbuminuria\n","concomitant\n","potassium supplements\n","potassium-sparing diuretics\n","strong CYP3A4 inhibitors\n","ACE-inhibitor\n","angiotensin receptor blocking agent\n","ACE-inhibitor and an angiotensin receptor blocking agent\n","potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent\n","Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;\n","Soft drusen\n","treated eye\n","fellow eye\n","treated eye or fellow eye\n","choroidal neovascularization\n","ophthalmoscopy\n","FA\n","ICGA\n","study eye\n","ophthalmoscopy and/or FA/ICGA\n","other cancers\n","at the same time\n","other cancers\n","except\n","controlled skin basal cell carcinoma\n","skin squamous cell carcinoma\n","carcinoma in situ of cervix uterus\n","controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus\n","active\n","infections\n","not\n","suitable for chemotherapy\n","severe\n","non-cancerous diseases\n","neoadjuvant hormone therapy\n","bilateral breast cancers\n","DCIS\n","metastatic breast cancers\n","anti-cancer therapies\n","attending other clinical trials\n","pregnant\n","lactational\n","contraception\n","refuse to practice\n","during the whole trial\n","The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish\n","allergic\n","tamoxifen\n","contraindication\n","allergic history or contraindication\n","primary breast cancer\n","Histologically confirmed\n","Histologically\n","docetaxel\n","Planned to start\n","FEC-D\n","AC-D\n","first cycle of\n","dose-dense AC-T\n","TC\n","FEC-D\n","TAC chemotherapy\n","FEC-D or AC-D\n","age\n","=19 years\n","Able to provide verbal consent\n","Thalassemia syndromes\n","Myelodysplastic syndrome (MDS)\n","myelofibrosis\n","Diamond Blackfan anemia\n","Primary bone marrow failure\n","LIC\n",">30 mg/g\n","Baseline\n","MRI\n","measured by\n","Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox\n","discontinuation of treatment\n","deferiprone\n","deferoxamine\n","deferiprone or deferoxamine\n","hypersensitivity\n","idiosyncratic reaction\n","deferiprone\n","deferoxamine\n","deferiprone or deferoxamine\n","hypersensitivity or idiosyncratic reaction\n","hydroxyurea\n","within 30 days\n","malignancy\n","abnormal\n","liver function\n","serum ALT level(s)\n","> 5 times upper limit of normal\n","at screening\n","creatinine levels\n",">2 times upper limit of normal\n","at screening\n","serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening\n","abnormal liver function\n","unstable illness\n","serious\n","as judged by the Investigator\n","during the past 3 months before screening/baseline visit\n","immunologic disease\n","hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease\n","Clinically significant\n","abnormal\n","12-lead ECG\n","findings\n","Cardiac MRI T2*\n","<10ms\n","Myocardial infarction\n","cardiac arrest\n","cardiac failure\n","within 1 year before screening/baseline visit\n","Myocardial infarction, cardiac arrest or cardiac failure\n","Unable to undergo\n","MRI\n","Presence of metallic objects such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas that would prevent use of MRI imaging\n","middle ear disease\n","chronic lung disease\n","claustrophobia\n","normotensive\n","forced expiratory volume in 1s : forced vital capacity ratio\n","> 0 75\n","no\n","medical history\n","respiratory disease\n","cardiovascular and respiratory disease\n","not\n","medications\n","other than\n","oral contraceptives\n","medications other than oral contraceptives\n","free from\n","sleep apnea\n","body mass index\n","less than 30 kg/m2\n","asthma\n","COPD\n","medical disease\n","acute\n","unstable\n","acute or unstable\n","psychiatric disease\n","alcoholism\n","drug abuse\n","primary sleep disorders\n","allergic rhinitis\n","Wheezing\n","hypersensitivity\n","statin\n","statins\n","during the past month prior to study\n","the past month prior to study\n","Serum creatinine\n","> 3 mg/dl\n","liver disease\n","liver enzymes\n","2 5 folds the upper normal limit\n","Significant\n","liver enzymes 2 5 folds the upper normal limit\n","Significant liver disease\n","Malignancy\n","Pregnancy\n","lactation\n","renal cancer\n","laparoscopic\n","radical nephrectomy\n","Contraindication\n","Filgrastim\n","The patients signed the written informed consent\n","operable\n","unilateral\n","invasive\n","breast cancers\n","distant\n","without\n","None\n","Skipping entity\n","I, II, and III\n","without distant\n","breast tumor\n","positive ER/PR rate\n","<1%\n","positive ER-beta1 rate\n","=10%\n","IHC\n","positive ER/PR rate is <1%, and positive ER-beta1 rate is =10%\n","neoadjuvant hormone therapy\n","no history\n","normal cardiac functions\n","echocardiography\n","ECOG scores\n","=0-2\n","Female\n","= 18yrs\n","= 65yrs\n","= 18yrs, and = 65yrs\n","The patients are non-pregnant, and disposed to practice contraception during the whole trial\n","neoadjuvant chemotherapy\n","surgery\n","radical mastectomy\n","directly modified\n","neoadjuvant chemotherapy plus surgery\n","breast-conserving surgery\n","sentinel lymph node biopsy\n","axillary lymph node dissection\n","after diagnosis of breast cancer\n","diagnosis of breast cancer\n","neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection)\n","chemotherapy\n","radiation therapy\n","targeted\n","None\n","Skipping entity\n","surgery\n","after surgery\n","surgery\n","2013 NCCN guideline\n","chemotherapy, radiation therapy or targeted therapy(herceptin)\n","The results of patients' blood tests are as follows:\n","Male\n","female\n","= 2 years\n","age\n","sickle cell disease\n","Hb electrophoresis\n","more specific tests\n","Hb electrophoresis or more specific tests\n","other conditions with iron overload\n","repeated\n","blood transfusions\n","Baseline LIC\n",">7 mg/g\n","MRI\n","no less than 20\n","transfusions of RBCs\n","in the last 2 years\n","transfusion\n","expected to have a continuing requirement\n","during the duration of the trial\n","deep peel\n","women\n","exoderm\n","older than 18 years\n","old\n","The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel\n","control\n",":\n",", skin\n","None\n","Skipping entity\n",": age, skin color and\n","insomnia\n","DSM-5\n","asthma\n","COPD\n","hypertension\n","history\n","impaired renal function\n","liver disease\n","heart failure\n","myocardial infarction\n","coronary artery disease\n","smoked\n","within the past year\n","apnea hypopnea index\n","> 5 events per hour\n","age\n","under 18y or over 85y\n","diabetes type 1\n","complications\n","co-operation\n","no\n","inadequate finnish language skills\n","persistent pain\n","other reason\n","severe\n","hepatic insufficiency\n","paracetamol\n","acetaminophen\n","contraindicated\n","steroid\n","regular use\n","oxycodone\n","contraindicated\n","paracetamol\n","acetaminophen\n","ropivacaine\n","regular use\n","paracetamol (acetaminophen) and/or ropivacaine\n","years\n","older than 18\n","both sexes\n","stable\n","chronic heart failure\n","NYHA class\n","II-III\n","ejection fraction\n","< 40 %\n","2D echocardiography\n","None\n","Skipping entity\n","antihistamine\n","within the past 72 hours\n","Chronic Pulmonary Condition\n","asthma\n","other\n","contraindication\n","cetirizine\n","asthma exacerbation\n","resuscitation\n","Severe\n","de novo\n","heart Failure\n","LVEF\n","<= 40%\n","admitted\n","hospital\n","without\n","contraindications\n","BB\n","pneumococcal infection\n","Vaccination\n","preparations of immune globulin\n","blood transfusion\n","within last three months prior to clinical studies\n","preparations of immune globulin or blood transfusion\n","more than 14 days\n","Prolonged use\n","immunosuppressants\n","other\n","immunosuppressive drugs\n","within 6 months prior to the start of the study\n","immunosuppressants or other immunosuppressive drugs\n","immunodeficient condition\n","HIV infection\n","immunosuppressive or immunodeficient condition\n","A history or currently hematologic and other cancers;\n","reaction for HIV infection\n","positive\n","reaction for HIV infection, viral hepatitis B and hepatitis C\n","cardio-vascular insufficiency\n","impaired liver\n","at visit number 1\n","respiratory, cardio-vascular insufficiency, impaired liver and kidney function\n","congenital defects\n","chronic diseases\n","acute stage\n","clinically important\n","serious\n","exacerbation\n","diseases of the liver\n","chronic\n","mental diseases\n","metabolic disorders\n","cystic fibrosis\n","lung abscess\n","empyema\n","active\n","tuberculosis\n","congestive heart failure\n","malabsorption\n","hepatic failure\n","chronic\n","renal and hepatic failure\n","cirrhosis\n","malignancy\n","immunodeficiency\n","cirrhosis of the liver\n","pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver\n","diseases of the liver, kidney, cardiovascular, nervous system\n","exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders\n","congenital defects or serious chronic diseases in the acute stage\n","Severe\n","allergic reactions\n","acute\n","communicable illnesses\n","within 1 month prior to study\n","infectious and/or communicable illnesses\n","alcohol abuse\n","drug use\n","chronic\n","alcohol abuse and/or drug use\n","Exacerbation\n","chronic diseases\n","Breastfeeding\n","Pregnancy\n","any other\n","within the last 3 months\n","study\n","greater than or equal to\n","None\n","Skipping entity\n","less than or equal to 89\n","greater than or equal to 40 and less than or equal to 89\n","between 90g and\n","a prostate\n","None\n","Skipping entity\n","lower urinary tract symptoms (\n","at least 6 months prior to study\n","to study\n","an IPSS\n","of at\n","13 at\n","at\n",": refractory to medical\n",", contraindicated to medical\n",", OR refuses medical\n",": refuses surgical\n","OR is contraindicated for surgical\n","None\n","Skipping entity\n",":\n","PSA < 4\n","None\n","Skipping entity\n",") OR\n","PSA >/=\n","prostate\n","AND a\n","(\n","12 core\n",") within the prior 12\n",": baseline PSA < 4 0ng/mL (no prostate biopsy required) OR baseline PSA >/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core\n",") OR baseline PSA >/= 4 ng/mL AND a negative\n","signed informed consent\n","lumbar decompression\n","single level\n","age\n","The subject is willing and able to understand, sign and date the study specific patient informed consent and HIPAA authorization to volunteer participation in the study\n","18 years old or more\n","old\n","HCV treatment\n","naive\n","HCV genotype\n","4\n","compensated\n","liver disease\n","healthy\n","postmenopausal\n","woman\n","hot flushes\n","At least 12\n","spontaneous\n","At least 6\n","spontaneous\n","serum follicle-stimulating hormone (FSH)\n","> 40 mIU/\n","At least 6 weeks\n","bilateral\n","(with or without\n","bilateral oophorectomy (with or without hysterectomy\n"," \n","bilateral\n","None\n","Skipping entity\n","serum FSH\n",">40 mIU/\n","At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/\n","At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy\n"," Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/\n","At least 12 months of spontaneous\n","At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/\n","Meets 1 of the\n","Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn  Eligible patients of reproductive potential should use adequate contraception if sexually active\n","Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety\n","Malignancy\n","within 5 years\n","treatment\n","localized\n","recent\n","non-invasive basal cell skin\n","permitted\n","squamous or non-invasive basal cell skin\n","cervical carcinoma in situ\n","allowed\n","treated\n","appropriately\n","prior to screening\n","subjects under evaluation for a malignancy are not eligible\n","hepatitis B virus (HBV)\n","human immunodeficiency virus (HIV)\n","Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit\n","hypersensitivity\n","LDV\n","SOF\n","LDV/SOF\n","bacterial infections\n","serious\n","at the time of screening\n","screening\n","Other significant medical conditions that could increase the risk to the subject\n","Females who are pregnant, breast feeding, or planning a pregnancy during the course study\n","None\n","Skipping entity\n","Type I diabetic\n","Parturients\n","Cesarean section\n","gestational age\n","at time of dilator insertion\n","dilator insertion\n","Able to read and write in English\n","Active cell phone with text messaging capability\n","Ride home\n","dilator insertion\n","Contraindications\n","BB\n","nursing home\n","Living\n","Life expectancy\n","< 6 months\n","Unable to self-care\n","mental disease\n","without caregiver\n","weight\n","Unable\n","phone\n","Without\n","Unable\n","go to clinic visit\n","both sexes\n","from 18 years\n","from 18 years\n","community-acquired pneumonia\n","COPD\n","Bronchial Asthma\n","The presence of signed and dated informed consent to participate in a clinical study;\n","The ability to perform the requirements of the Protocol;\n","For women of childbearing age is a negative result of a pregnancy test before vaccination\n","radiologically confirmed\n","radiologically\n","infiltration of the lung tissue\n","at least two\n","acute fever\n","early in the disease\n","temperature\n","> 38 0°C\n","cough with sputum\n","pneumonia\n","physical signs\n","fine bubble rales\n","bronchial breathing hard\n","shortening of percussion sounds\n","crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds\n","physical signs of pneumonia\n","leukocytosis\n","> 10*10 9 /l\n","stab shift\n","> 10%\n","acute fever early in the disease (temperature > 38 0°C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%\n","dyspnea\n","community-acquired pneumonia\n","radiologically confirmed infiltration of the lung tissue; the presence of at least two of the following clinical signs: acute fever early in the disease (temperature > 38 0°C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%\n","progressive\n","worsens over time\n","increases with exertion\n","persistent\n","chronic cough\n","chronic expectoration\n","Smoking\n","risk factors\n","occupational dust pollutants and chemicals\n","wheeze on auscultation of the chest\n","distant wheezing in the chest\n","widespread\n","family history\n","COPD\n","spirometric\n","fixed bronchial obstruction\n","Smoking, occupational dust pollutants and chemicals\n","progressive (worsens over time), increases with exertion, persistent\n","COPD\n","dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction\n","seizure disorder\n","childhood febrile seizure\n","single\n","History\n","None\n","Skipping entity\n","None\n","Skipping entity\n","major depressive\n",", bipolar\n",", psychotic\n","generalized anxiety\n","requiring\n","major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety\n","clinically important hepatic or renal disease or other medical\n","other than\n","hepatocellular carcinoma (HCC)\n","liver cirrhosis\n","decompensated\n","Child-Pugh score\n","above 6\n","genotype 4\n","non\n","liver disease\n","liver function test\n","abnormality\n","renal disease\n","glomerular filtration rate\n","< 60mL/min/1 73m2\n","opioid\n","baseline\n","pre-operative\n","greater than 30 mg of morphine equivalents/day\n","alcohol dependence\n","illicit drug dependence\n","age\n","< 18 years\n","age\n",">70 years\n","allergic\n","medication\n","seizure disorder\n","rectal cancer\n","transurethral resection of the prostate (TURP\n","open prostate\n","None\n","Skipping entity\n","microwave\n","pelvic\n","  Patient is unwilling to discontinue alpha blockers 1 month after study\n","alpha\n","5-alph reductase\n","1 month after study\n","study\n","1 month after study\n","  Patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study\n","  Neurogenic\n","neurologic disorder impacting bladder\n","as Parkinson's\n",", multiple\n",", cerebral vascular\n","or\n","or urethral\n","or urethral\n","urethral\n",", bladder neck\n",", or bladder\n","bladder or urethral\n","urethral stricture, bladder neck contracture, or bladder\n","Active\n","or urinary tract\n","None\n","Skipping entity\n","  \n","within the past\n","months   Serum\n",">\n","oral\n","2-5 days prior to study\n","prior to study\n","7mg/dL   Inability to discontinue oral anticoagulant 2-5 days prior to study\n","  Coagulation\n","  Coagulation\n","by\n","not\n","None\n","Skipping entity\n","None\n","Skipping entity\n","treatment   \n","treatment   Iodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately\n","  \n","None\n","Skipping entity\n","Known severe peripheral\n","None\n","Skipping entity\n","or major iliac arterial\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","disease   Interest in\n","disease   Interest in\n","significant\n","or other\n","(including\n","), uncontrolled\n","heart\n","significant\n","mellitus,\n","mellitus,\n","mellitus,\n",", or known\n","  Other condition that the Investigator believes puts the patient at risk for a complication\n","  Other condition that the Investigator believes puts the patient at risk for a complication\n","Contraindications\n","spinal anesthesia\n","bleeding diathesis\n","regional infection\n","site of neuroaxial block\n","bleeding diathesis or regional infection\n","allergy\n","Granisetron\n","local anaesthetic\n","heavy bupivacaine\n","Marcaine Spinal 0 5% Heavy\n","5mg/ml\n","AstraZeneca ampule\n","heavy bupivacaine, Marcaine Spinal 0 5% Heavy, 5mg/ml, AstraZeneca ampule\n","Granisetron or local anaesthetic (heavy bupivacaine, Marcaine Spinal 0 5% Heavy, 5mg/ml, AstraZeneca ampule)\n","Pregnancy\n","hypertension\n","Pregnancy induced\n","Congenital\n","rheumatic\n","heart diseases\n","Congenital or rheumatic\n","Antepartum haemorrhage\n","Fetal destress\n","gestational age\n","< 36 week\n","The subject must be willingly and able to provide written informed consent\n","19 years of age or older\n","Age\n","(The age of consent in Nebraska)\n","naïve\n","treatment\n","HCV\n","Interferon (IFN)\n","RBV\n","other FDA approved or experimental HCV-specific direct-acting antiviral agent\n","no\n","prior\n","Interferon (IFN), RBV\n","HCV treatment-naïve\n","no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent\n","HCV RNA level\n","at most 6 months prior to the Baseline/Day 1 visit\n","the Baseline/Day 1 visit\n","HCV genotyping\n","1a, 1b, or mixed 1a/ab\n","Any non-definitive results will exclude the subject from study participation\n","Alcohol misuse\n","Alcohol Use Disorders Identification Test (AUDIT) score\n","> 8\n","liver biopsy\n","cirrhosis\n","Metavir score\n","Ishak score\n","= 4\n","> 5\n","Metavir score = 4 or Ishak score > 5\n","Fibroscan\n","cirrhosis\n","> 12 5 kPa\n","cirrhosis or results > 12 5 kPa\n","FIBRO Spect II index\n","platelet ration index (APRI)\n","> 2\n","during Screening\n","F3 or F4\n","AST\n","Liver biopsy\n","within 2 years of Screening\n","cirrhosis\n","absence\n","Fibroscan\n","within 6 months of Baseline/Day1\n","= 12 5 kPa\n","FIBRO Spect II Index\n","F0- F2\n","APRI\n","= 1\n","during Screening\n","Liver imaging\n","within 6 months of Baseline/Day 1\n","hepatocellular carcinoma HCC)\n","exclude\n","ALT\n","AST\n","< 10 x the upper limit of normal (ULN)\n","< 10 x ULN\n","Direct bilirubin\n","< 2 0 x ULN\n","Platelets\n","> 50,000\n","HbA1c\n","< 8 5%\n","Creatinine clearance (CLcr)\n","= 60 mL /min\n","Cockcroft-Gault equation\n","Hemoglobin\n","= 11 g/dL\n","female\n","= 12 g/dL\n","male\n","= 11 g/dL for female subjects; = 12 g/dL for male\n","Albumin\n","= 2 5 g/dL\n","INR\n","= 1 5 x ULN\n","hemophilia\n","stable on an anticoagulant regimen affecting INR\n","unless\n","hemophilia or is stable on an anticoagulant regimen affecting INR\n","None\n","Skipping entity\n","Male\n","female\n","IgPro20\n","Hizentra\n","stable dose\n","Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening\n","PID\n","common variable immunodeficiency\n","X-linked agammaglobulinemia\n","Pan American Group for Immune Deficiency\n","European Society of Immune Deficiencies\n","and\n","Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies\n","common variable immunodeficiency or X-linked agammaglobulinemia\n","pump-assisted infusions\n","IgPro20\n","flow rate of 25 mL/h per injection site\n","tolerated\n","for at least 1 month prior to Day 1\n","Day 1\n","weekly\n","IgPro20\n","= 50 mL\n","10 g\n","pump-assisted infusions\n","IgPro20\n","volumes of 25 mL/injection site\n","tolerated\n","for at least 1 month prior to Day 1\n","Day 1\n","frequent\n","IgPro20\n","25-30 mL/h\n","for at least 1 month prior to Day 1\n","Day 1\n","2-7 times per week\n","not\n","None\n","Skipping entity\n","gabapentin\n","Current\n","pregabalin\n","gabapentin or pregabalin\n","Allergy\n","gabapentin\n","acetaminophen\n","codeine\n","ibuprofen\n","gabapentin, acetaminophen, codeine, or ibuprofen\n","Self reported\n","renal disease\n","severe\n","impaired renal function\n","Self reported renal disease\n","severe impaired renal function\n","Self reported\n","current\n","chronic\n","narcotic use\n","current or chronic\n","daily use\n","Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data\n","years\n","over 18\n","weighing\n","between 65 and 85 Kg\n","STEMI\n","loading dose\n","Prasugrel\n","Ticagrelor\n","Prasugrel or Ticagrelor\n","within 6 hours from beginning of chest pain\n","beginning of chest pain\n","coronary artery disease\n","stable\n","No\n","Clopidogrel\n","Prasugrel\n","Ticagrelor\n","Clopidogrel, Prasugrel or Ticagrelor\n","fasting\n","for at least 6 hours\n","Affiliate or receiving a social security system\n","chest pain\n","previous\n","treatment\n","Written informed consent\n","Immunocompromised\n","immunodeficiency\n","acquired\n","congenital\n","congenital or acquired\n","chemotherapy\n","less than 6 weeks ago\n","corticosteroids\n","in the last 6 weeks\n","immunosuppressive medication\n","in the last 6 weeks\n","cyclosporin\n","cyclophosphamide\n","azathioprine\n","cyclosporin, cyclophosphamide, azathioprine\n","chronic obstructive pulmonary disease\n","systemic corticosteroids\n","intensive care unit\n","tropical worm infection\n","dexamethasone\n","intolerance\n","Pregnant and breastfeeding women\n","Type 1 diabetes\n","diabetes mellitus type 2\n","uncontrolled\n","fasting glucose\n","> 13 3 mmol/l\n","hypersensitivity\n","empagliflozin\n","glimepiride\n","hypersensitivity\n","sulfonylureas\n","sulfonamides\n","SGLT2 inhibitors\n","sulfonylureas, sulfonamides or SGLT2 inhibitors\n","empagliflozin, glimepiride\n","hypoglycemic episodes\n","severe\n","multiple\n","last two years\n","Insulin\n","SGLT2-inhibitor\n","sulfonylurea derivate\n","glinide\n","Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide\n","past 3 months\n","macular edema\n","both eyes\n","intravitreal anti-VEGF treatment\n","both eyes\n","Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included  Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included\n","prevent\n","ophthalmoscopy\n","vitreous hemorrhage\n","mature cataract\n","macular pathologies\n","other\n","diabetic maculopathy\n","ketoacidosis\n","metabolic acidosis\n","loop diuretics\n","urogenital infection\n","stroke\n","transient ischemic attack\n","TIA\n","angina pectoris\n","instable\n","myocardial infarction\n","last 3 months prior to baseline visit\n","baseline visit\n","stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction\n","congestive heart failure\n","New York Heart Association\n","NYHA\n","III and IV\n","left ventricular outflow obstruction\n","severe\n","valvular or left ventricular outflow obstruction disease\n","intervention\n","atrial fibrillation\n","mean ventricular response rate\n","at rest\n",">100 beats per minute\n","atrial fibrillation/flutter\n","lower urinary tract infections\n","chronic\n","not\n","asymptomatic bacteriuria\n","eGFR\n","< 60 ml/min/1,73 m2\n","chronic diarrhea\n","volume depletion\n","hematocrit\n","> 48 %\n","women\n","> 53 %\n","men\n","hematocrit\n","hematocrit > 48 % (women) and > 53 % (men)\n","risk for volume depletion,\n","elevated\n","chronic liver disease\n","active hepatitis\n","alanine transaminase\n","ALT\n","aspartate transaminase\n","AST\n","> 3 x upper limit of normal\n","alanine transaminase (ALT) or aspartate transaminase (AST)\n","human immunodeficiency virus\n","seropositivity\n","acute illness at screening or randomization according to judgement by the investigator or patient\n","alcohol abuse\n","psychiatric diseases\n","hospitalization\n","last 12 months\n","psychosomatic or psychiatric diseases\n","malignancy\n","exception\n","squamous cell carcinoma of the skin\n","cervical intraepithelial neoplasia\n","5 years prior to randomization\n","randomization\n","basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia\n","medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigator´s judgment\n","current participation in any other clinical trial or participation in another clinical trial within 30 days before screening\n","Subjects with any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study\n","Pregnancy or lactation\n","allergic\n","tranexamic acid\n","4 weeks preceding inclusion\n","inclusion\n","planned participation\n","Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n","Participation in the 4 weeks preceding inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n","None\n","Skipping entity\n","in the 4 weeks preceding each trial\n","each trial\n","in the 4 weeks following each trial\n","each trial\n","planned\n","None\n","Skipping entity\n","except for\n",") influenza\n","at least 2 weeks before study\n","study\n","except\n","concomitantly with the first dose of study\n","the first dose of study\n",") measles (M) or measles, mumps, rubella (MMR) routine\n","at Indian\n",": oral poliomyelitis vaccine (\n","during National Immunization Days (\n","National Immunization Days (\n","and supplementary immunization activity days (\n","during National Immunization Days (NIDs) and supplementary immunization activity days (\n","vaccination against meningococcal\n","the study\n","or another meningococcal\n","of immune\n",",\n","or blood-derived\n","in the past 3\n","of immune globulins, blood or blood-derived\n","or acquired\n","of immunosuppressive\n","as anti-cancer\n","or radiation\n",", within the preceding 6\n","-term systemic corticosteroid\n","; or\n","(\n","for more than 2\n","weeks within the past 3\n","as anti-cancer chemotherapy or radiation\n","or\n","None\n","Skipping entity\n","  Known or\n","congenital or acquired\n","of meningococcal\n",",\n",", or\n",",\n","  At high risk, in the opinion of the Investigator, for meningococcal disease during\n","  At high risk, in the opinion of the Investigator, for meningococcal disease during\n","suspected systemic\n","of the vaccine\n",",\n","of a life-\n","to\n","or to\n","vaccine used in\n","vaccine used in\n","trial   Known or suspected systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same\n","  Known\n",",\n","intramuscular\n","  \n","receipt of\n","in the 3 weeks\n","None\n","Skipping entity\n","inclusion,\n","intramuscular\n","  Bleeding disorder, or receipt of\n","  In an\n","setting, or\n","hospitalized\n","setting, or hospitalized\n","  Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct\n","enrolled\n","Indian\n",":\n","or\n","/infection (according to\n","judgment) on the day\n","judgment) on the day\n","vaccination or\n","None\n","Skipping entity\n","(\n","or severe acute\n","Indian sites:\n","Indian sites: Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (\n","enrolled\n","Russian\n","of any severity on the\n","any severity on the\n","vaccination or\n","illness (\n","None\n","Skipping entity\n","Russian sites: Acute disease of any severity on the day of vaccination or febrile illness (axillary\n","≥ 37 0°C)    A prospective subject should not be included in the study until the condition has resolved or the febrile\n","≥ 37 0°C)    A prospective subject should not be included in the study until the condition has resolved or the febrile\n","or injectable\n","of\n","None\n","Skipping entity\n","   Receipt of\n","therapy within 72 hours prior to\n","72 hours prior to\n","first blood draw   Identified as a natural or adopted child of the Investigator or employee with direct involvement in\n","Personal history of\n","None\n","Skipping entity\n","Dupuytrens contracture\n","symptomatic\n","palpable cord\n","involving MCP\n","total contracture size\n","over 30 degrees\n","Allergy\n","contraindication\n","paracetamol\n","Prasugrel\n","Ticagrelor\n","paracetamol, Prasugrel or Ticagrelor\n","Allergy or contraindication\n","Paracetamol\n","in the previous 48 hours\n","calcium antagonists\n","Alimentary tract treatments\n","opioid analgesics\n","tricyclic antidepressants\n","antibiotics\n","Thyroid dysfunction\n","chronic renal failure\n","Parkinson's disease\n","scleroderma\n","amyloidosis\n","gastrointestinal disease\n","malignancy\n","neurological disease\n","advanced\n","psychiatric or neurological disease\n","vomiting\n","Cardiogenic shock\n","ventricular arrhythmia\n","cardiac arrest\n","resuscitated\n","Hepatic insufficiency\n","respiratory disease\n","Severe\n","drugs supposed to alter gastric emptying times\n","calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics\n","pathologies supposed to alter gastric emptying times\n","Conditions or pathologies supposed to alter gastric emptying times\n","Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease\n","Pregnant\n","breastfeeding\n","women\n","years\n","Chest radiograph\n","opacities\n","new\n","Cough\n","sputum\n","Temp\n",">38,0 °C\n","<36,0 °C\n",">38,0 °C or <36,0 °C\n","Audible abnormalities\n","chest examination\n","pneumonia\n","Leukocytosis\n",">10 000 cells/mm3\n","leucopenia\n","<4000 cells/mm3\n",">10 000 cells/mm3), leftward shift (>10%)\n","C-reactive protein\n","> 15 mg/l\n","three fold higher than the upper limit of normal\n","women\n","men\n","age\n","between 18 - 80 years\n","type 2 diabetes mellitus\n","diabetic retinopathy\n","early\n","moderate stage\n","early to moderate stage\n","ETDRS\n","20\n","35\n","20 (microaneurysms only) to 35\n","eyes\n","HbA1c\n","± 0 5%\n","at least 12 weeks\n","antidiabetic treatment\n","diet\n","metformin\n","DPP4\n","GLP1\n","pioglitazone\n","acarbose\n","diet, metformin, DPP4, GLP1, pioglitazone, acarbose\n","HbA1c\n","= 6 5 and = 10 0 %\n","body mass index\n","< 46 kg/m2\n","blood pressure\n","= 150/95 mmHg\n","(confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines\n","surgical sterilization\n","bilateral tubal ligation\n","bilateral oophorectomy\n","bilateral tubal ligation or bilateral oophorectomy\n","at least 6 weeks\n","hysterectomy\n","years\n","= 50\n","postmenopausal state\n","> 1 year\n","< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication\n","correct use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e g  condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)\n","true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)\n","sexual relationship only with female partners\n","sterile male partners\n","signed written informed consent and willingness to comply with treatment and follow-up procedures\n","capability of understanding the investigational nature, potential risks and benefits of the clinical trial\n","scheduled for\n","dental extraction\n","edoxaban\n","apixaban\n","rivaroxaban\n","dabigatran\n","edoxaban, apixaban, rivaroxaban or dabigatran\n","on the day of the extraction\n","extraction\n","Not\n","anticoagulant\n","oral\n","Provision of signed and dated informed consent form\n","Stated willingness to comply with all study procedures and availability for the duration of the study\n","Male\n","female\n","aged\n","9 to 17 months\n","on the day of inclusion\n","the day of inclusion\n","and\n","Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable\n","  Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial\n","  Subject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial\n","previous\n","treated\n","dupuytrens contracture\n","same hand\n","more than tree\n","fingers involvement\n","we will not include thumbs\n","other things\n","affecting hand function\n","None\n","Skipping entity\n","None\n","Skipping entity\n","expected to live\n","under five years\n","Tetracycline\n","within two weeks\n","pregnancy\n","nursing\n","allergy\n","clostridium histolyticum\n","participant in other trial\n","The patient is participating in another clinical study using an investigational product\n","The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study\n","coagulopathy\n","anti-coagulation therapy\n","Gastrointestinal disease\n","motion sickness\n","diabetes mellitus\n","preeclampsia\n","Age\n","<18 years old\n","Patient unable to communicate or to understand the study\n","Patient refusing to participate to the study\n","contraindication\n","laparoscopy\n","Age\n","14 to 65 years-old\n","Port-wine Stain\n","hemoporfin\n","Written informed consent signed and agreed to receive periodic follow-up\n","behavioral issues\n","severe\n","fistula\n","abscess\n","near the selected tooth\n","fistula or abscess\n","pulp exposure\n","selected tooth\n","mobility\n","selected tooth\n","kidney transplants\n","De novo\n","old\n","20 - 65 years\n","alanine aminotransferase\n","aspartate aminotransferase\n","within 2 times the upper limit of normal range\n","aspartate aminotransferase/alanine aminotransferase\n","The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent\n","GAA enzyme deficiency\n","skin\n","blood\n","muscle tissue\n","2\n","GAA gene mutations\n","skin, blood, or muscle tissue\n","Pompe disease\n","Infant\n","toddler\n","Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time\n","The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening  Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study\n","For patients previously treated with alglucosidase alfa\n","alglucosidase alfa\n","for at least 6 months\n","women\n","pelvic floor dysfunction\n","consent\n","adult\n","female\n","female partner\n","aged\n","18 to 40 years\n","cesarean section\n","elective\n","scheduled for\n","Pregnancy\n","Tuberculosis\n","Human immunodeficiency virus\n","positive\n","Retransplantation\n","transplantation\n","multiorgan\n","rheumatoid arthritis\n","Use of drugs that might have enhanced or inhibited CYP3A4 or P-gp activity\n","Allergy\n","porphyrins\n","Photosensitivity\n","Porphyria\n","Allergic constitution\n","porphyrins and analogues\n","Scar diathesis\n","Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application\n","Be judged not suitable to participate the study by the investigators\n","Children\n","aging\n","between 3 and 6 years\n","good health conditions\n","whose parents or legal guardians accept and sign the consent form\n","at least one\n","occlusal proximal\n","occlusal\n","caries lesion\n","primary molars\n","occlusal or occlusal proximal\n","caries lesions\n","dentin involvement\n","occlusal-proximal surfaces\n","occlusal and/or occlusal-proximal surfaces\n","caries lesions with dentin involvement\n","Aged\n","=18 years\n","acute coronary syndrome\n","dual anti-platelet therapy\n","aspirin\n","P2Y12 receptor antagonist\n","requires\n","Resident\n","Scotland\n","Community Health Index (CHI) number\n","The attending clinician has equipoise regarding the duration of therapy\n","Provision of informed consent\n","age\n","= 70 years\n","noncardiac surgical procedure\n","general anesthesia\n","anticipated\n","duration of postoperative admission\n","at least 2 days\n","admission\n","postoperative\n","None\n","Skipping entity\n","growth factor receptor\n","< 50mL/min\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","aminotransaminase\n",">2 5 upper limit of normal\n","AST(aspartate aminotransferase)/ALT(alanine aminotransaminase\n","Pregnant or lactating women\n","Subject who the investigator deems inappropriate to participate in this study\n","bladder cancer\n","active\n","bladder cancer\n","macroscopic hematuria\n","uninvestigated\n","cardiac failure\n","history of cardiac failure\n","3 to 4\n","NYHA\n","cardiac failure or a history of cardiac failure\n","genetic problems\n","galactose intolerance\n","Lapp lactase deficiency\n","glucose-galactose malabsorption\n","galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\n","drug abuse\n","history\n","history\n","schizophrenia\n","preoperative\n","epilepsy\n","parkinsonism\n","cholinesterase inhibitor\n","inability to communicate\n","coma\n","profound dementia\n","language barrier\n","diabetes\n","hypertension\n","cardiac disease\n","asthma\n","chronic obstructive lung disease\n","diabetes, hypertension, cardiac disease, asthma, chronic obstructive lung disease\n","medical illness\n","acute\n","chronic\n","acute or chronic\n","nicotine use\n","tobacco or nicotine use\n","last 60 days\n","sickle cell trait\n","hereditary hematological abnormality\n","fainting\n","phlebotomy\n","adverse reaction\n","donation of blood\n","phlebotomy or donation of blood\n","QTc\n","electrocardiogram\n",">470 ms\n","alcohol abuse\n","Hepatitis C infection\n","thrombophilia\n","anticoagulant therapy\n","Pregnancy\n","None\n","Skipping entity\n","Obesity\n","None\n","Skipping entity\n","blood donation\n",") Single whole blood unit donation within the past 8 weeks; b) Double RBC donation by apheresis within the past 16 weeks; or c) Plasma donation by apheresis within the past 4 weeks\n","RBC mass\n","Inadequate\n","TBV\n","<4500 ml\n","Hb\n","<14 g/dL\n","TBV <4500 ml (above) or screening Hb <14 g/dL\n","Ambulatory status\n","outpatient\n","at time of consent\n","10-55\n","None\n","Skipping entity\n","Autism Spectrum\n","None\n","Skipping entity\n","IQ greater than or equal to\n","on Children's Yale-Brown Obsessive Compulsive\n","greater\n","of psychoactive\n","  \n","for\n","None\n","Skipping entity\n","and\n","SSRIs and\n","for\n","prior to MRI\n",") of anticonvulsant\n","for seizure\n","(greater than three\n","stable\n","for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for\n","[\n","  Clinical\n","primary knee osteoarthritis\n","Kellgren & Lawrence\n","I, II or III\n","radiologic diagnosis\n","Capability to understand the Informed Consent Form\n","Capability to understand the Informed Consent Form\n","  Chronic\n","at least 3 months\n","None\n","Skipping entity\n","None\n","Skipping entity\n",", measured by\n"," (\n","4 or\n"," (VAS 4 or above\n","of skin\n","  \n",",\n","or\n","target\n",";   Availability to comply with the\n",";   Availability to comply with the\n","breast cancer\n","unilateral mastectomy\n","undergoing\n","axillary node dissection\n","received adequate oral and written information about the study and signed an informed-consent form\n","Age\n","= 18 years\n","NYHA (New York Heart Association) functional class\n","II, III and IV\n","premenopausal\n","women\n","BRCA1 carrier\n","endometrial hyperplasia\n","atypia\n","estrogen-progestin therapy\n","in the 2 months before enrollment\n","autoimmune diseases\n","endocrine disorders\n","hyperandrogenism\n","hyperprolactinemia\n","diabetes mellitus\n","thyroid disease\n","hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease\n","chronic, metabolic, systemic and endocrine disorders\n","hypogonadotropic hypogonadism\n","majors clinical conditions\n","neurological condition\n","pain diagnosis\n","other than\n","associated with their pain diagnosis\n","in the opinion of the investigator\n","lidocaine-containing\n","could not be\n","while receiving\n","None\n","Skipping entity\n","receiving\n","class 1 anti-arrhythmic\n",",\n",",\n",", mexiletine,\n","Habitual exerciser defined as = 30 minutes of at least moderate or high intensity exercise = 3 times per week  After consent, and at the subsequent screening visit, a VO2 max test will be performed, and subjects with a low value (< 35 mL/kg/min) will be excluded (screen failure)  Based on our previous experience, we anticipate that <10% of the subjects will fall into this category\n","Men\n","TBV\n","(0 006012 x H3) + (14 6 x W) + 604 =\n","Women\n","TBV\n","(0 005835 x H3) + (15 x W) + 183\n","None\n","Skipping entity\n","Completed \"ALO-IIT-012(PEAK study)\", without major protocol deviations\n","Male\n","female\n","years\n","19 years to 75\n","Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study\n","Subjects completed PEAK can be included within 30 days after End Of the Study\n","Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study\n","age\n","> 17 and < 60 years\n","American Society of Anesthesiology (ASA)\n","I-III\n","living donor renal transplantation\n","admitted for\n","dual anti-platelet therapy\n","Clear indication for specific duration\n","Type 2 myocardial infarction\n","Contraindication\n","aspirin\n","P2Y12 receptor antagonist\n","aspirin or P2Y12 receptor antagonist\n","Non-resident\n","Scotland\n","Previous recruitment into the trial\n","Inability or unwilling to give informed consent\n","1) preoperative diagnosis of delirium or dementia;\n","2) MMSE score of = 20 out of 30 on preoperative testing (more than mild cognitive impairment) or delirium on preoperative CAM testing;\n","3) language barriers that would preclude testing;\n","4) preoperative steroid use within 3 days of surgery;\n","None\n","Skipping entity\n","delirium\n","dementia\n","preoperative\n","delirium or dementia\n","MMSE score\n","= 20 out of 30\n","preoperative\n","more than mild\n","cognitive impairment\n","MMSE score of = 20 out of 30\n","more than mild cognitive impairment\n","delirium\n","preoperative\n","CAM testing\n","language barriers\n","preoperative\n","steroid\n","within 3 days of surgery\n","surgery\n","surgery\n","postoperative\n","intubation\n","anticipation\n","spinal cord stenosis\n","History\n","lumbar radiculopathy\n","clinical symptoms\n","neurological\n","None\n","Skipping entity\n","None\n","Skipping entity\n","History or\n","  Generalized\n","None\n","Skipping entity\n","  Inability to\n","of knee\n","the target\n",";   \n","of\n",";   Secondary\n",";   Secondary causes of\n","of\n","and\n","in the\n","psychiatric\n","and\n",";   \n",";   Invasive knee\n","with\n","with hyaluronic acid\n",",\n","and\n","in the\n","knee, up to 6 months\n","to study\n",";   Invasive knee treatments with hyaluronic acid infusion, corticosteroids and\n","Age\n","less than 10 years\n","greater than 55 years\n","less than 10 years or greater than 55 years\n","at time of consent\n","Estimated\n","<\n","  Uncontrolled\n","within 6 months prior to\n","(\n","4  Presence of medical conditions that might interfere with participation, or where participation would be\n","of neurological\n","  \n",": head\n","seizure\n",", poorly-\n","(\n","within the preceding six\n","),\n","None\n","Skipping entity\n",",\n","or under the care of a\n",": head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or\n","of\n","  \n","or irremovable metal in\n","None\n","Skipping entity\n","-up)   \n","(as verified by testing prior to both initial dose administration of citalopram or placebo and prior to magnetic resonance imaging) due to the risk that may be associated with SSRI treatment and magnetic resonance imaging on fetal\n","Medical contraindications to SSRI\n","None\n","Skipping entity\n","during SSRI\n","or\n","of mania or\n","known drug\n","by\n",")   Concomitant medication that would interfere with study\n","of\n","  \n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","  Prior history of citalopram treatment failure at appropriate doses\n","duration   Prior history of treatment failure to two previous SSRI trials at appropriate doses\n","need for\n","other than\n","[excepting\n","doses (greater than\n",") of\n","for\n",", or\n","medication [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder, or diphenhydramine (\n","None\n","Skipping entity\n","None\n","Skipping entity\n","consent\n","consent\n","to SSRI\n","of mania or hypomania during SSRI therapy, or known drug\n","PHN\n","DN\n","CRPS\n","carpal tunnel syndrome\n","HIV neuropathy\n","neuropathy\n","HIV\n","sensory neuropathy\n","idiopathic\n","peripheral neuropathy\n","None\n","Skipping entity\n",">3\n","after rash\n","rash\n","rash\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","None\n","Skipping entity\n","sensorimotor\n","dynamic\n","Type I or II diabetes and painful distal symmetric sensorimotor\n","upon mutual agreement of the sponsor and investigator\n","None\n","Skipping entity\n","IASP (International Association for the Study of Pain) diagnostic\n","None\n","Skipping entity\n","carpal tunnel\n","clinical neurological\n","and Tinel's\n","g , Phalen's and Tinel's\n","),\n","and\n","of at least 3 months'\n","painful\n","with HIV\n","None\n","Skipping entity\n","HIV, subjective\n","peripheral\n","of\n","and\n","painful\n","of at least 3 months'\n","had HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months'\n","with idiopathic sensory\n","None\n","Skipping entity\n","of at least 3 months'\n","daily pain\n","rating during the\n","the\n","an\n","greater\n","on the 0-to-10 numerical pain\n","an analgesic\n","None\n","Skipping entity\n","or\n","lidocaine or\n","submucosal\n","subserosal leiomyomas\n","symptoms\n","menometrorrhagia\n","menstrual disorder\n","infertility\n","pelvic pain\n","Anaphylactic reaction\n","influenza vaccine\n","None\n","Skipping entity\n","IgE( Immunoglobulin E)-mediated hypersensitivity\n","eggs\n","hives\n","swelling of the mouth and throat\n","difficulty in breathing\n","hypotension\n","shock\n","hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock\n","Guillain-Barré syndrome\n","within eight weeks of a previous influenza vaccine\n","a previous influenza vaccine\n","previous\n","influenza vaccine\n","Anaphylactic reaction\n","neomycin\n","influenza vaccine\n","in two of the three previous years\n","pregnant\n","breastfeeding\n","thromboembolic disease\n","high risk of\n","thromboembolism\n","extra anticoagulation\n","allergy\n","tranexamic acid\n","Cyklokapron\n","tranexamic acid/Cyklokapron\n","History\n","allergic reaction\n","compounds of similar chemical or biologic composition to hCG\n","hCG\n","medication\n","could interfere with the study protocol objectives\n","hormonal contraceptives\n","androgens\n","prednisone\n","thyroid hormones\n","insulin\n","hormonal contraceptives, androgens, prednisone, thyroid hormones, insulin\n","previous\n","receiving\n","treatment\n","follicle stimulating hormone\n","assisted reproduction\n","uncontrolled\n","intercurrent illness\n","Heart disease\n","Severe\n","cognitive decline\n","Psychiatric desease\n","HIV positive\n"]}]},{"cell_type":"code","source":[],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":174},"id":"y1wHkIQiZ-eP","executionInfo":{"status":"error","timestamp":1700444794775,"user_tz":300,"elapsed":147,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"fa29f23c-8bbc-47f0-ab73-31313fbb26cb"},"execution_count":20,"outputs":[{"output_type":"error","ename":"TypeError","evalue":"ignored","traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)","\u001b[0;32m<ipython-input-20-1e14c1957ad8>\u001b[0m in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc_bin\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_docs\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m","\u001b[0;31mTypeError\u001b[0m: DocBin.get_docs() missing 1 required positional argument: 'vocab'"]}]},{"cell_type":"code","source":["# training from artificial data (LOCATION, AGE, DISEASE)\n","from spacy.util import filter_spans\n","\n","training_data = []\n","\n","for example in data[\"data\"]:\n","  temp_lst = []\n","\n","  text = example['entities'][0]['text']\n","\n","  labels = []\n","  for entity in example['entities']:\n","    start = entity['indexes'].split(',')[0]\n","    end = entity['indexes'].split(',')[1]\n","    label = entity['label']\n","    labels.append((start, end, label))\n","\n","  doc = nlp.make_doc(text)\n","  ents = []\n","\n","  for start, end, label in labels:\n","    span = doc.char_span(int(start), int(end), label=label, alignment_mode=\"contract\")\n","    if span is None:\n","      print(\"Skipping entity\")\n","    else:\n","      ents.append(span)\n","  filtered_ents = filter_spans(ents)\n","  doc.ents = filtered_ents\n","  doc_bin.add(doc)\n","\n","doc_bin.to_disk(\"train.spacy\")\n"],"metadata":{"id":"LOrqOVdguRAB"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["for doc in doc_bin.get_docs(nlp.vocab):\n","    # Now you can work with each Doc object\n","    print(doc.cats)"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":1000},"id":"Gubl9D4CZpN-","executionInfo":{"status":"error","timestamp":1700447512588,"user_tz":300,"elapsed":5488,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"e625c41b-2e99-41db-f14b-86b83a3a0cbc"},"execution_count":52,"outputs":[{"output_type":"stream","name":"stdout","text":["\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n","{}\n"]},{"output_type":"error","ename":"KeyboardInterrupt","evalue":"ignored","traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)","\u001b[0;32m<ipython-input-52-7983e7254445>\u001b[0m in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0;32mfor\u001b[0m \u001b[0mdoc\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdoc_bin\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_docs\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnlp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvocab\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m     \u001b[0;31m# Now you can work with each Doc object\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcats\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;32m/usr/local/lib/python3.10/dist-packages/spacy/tokens/_serialize.py\u001b[0m in \u001b[0;36mget_docs\u001b[0;34m(self, vocab)\u001b[0m\n\u001b[1;32m    148\u001b[0m                 \u001b[0mspaces\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    149\u001b[0m             \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mDoc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvocab\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwords\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtokens\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0morth_col\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mspaces\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mspaces\u001b[0m\u001b[0;34m)\u001b[0m  \u001b[0;31m# type: ignore\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 150\u001b[0;31m             \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfrom_array\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mattrs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtokens\u001b[0m\u001b[0;34m)\u001b[0m  \u001b[0;31m# type: ignore\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    151\u001b[0m             \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcats\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcats\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    152\u001b[0m             \u001b[0;31m# backwards-compatibility: may be b'' or serialized empty list\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;32m/usr/local/lib/python3.10/dist-packages/spacy/tokens/doc.pyx\u001b[0m in \u001b[0;36mspacy.tokens.doc.Doc.from_array\u001b[0;34m()\u001b[0m\n","\u001b[0;32m/usr/local/lib/python3.10/dist-packages/numpy/core/_methods.py\u001b[0m in \u001b[0;36m_any\u001b[0;34m(a, axis, dtype, out, keepdims, where)\u001b[0m\n\u001b[1;32m     52\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0mumr_prod\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ma\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mout\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkeepdims\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minitial\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwhere\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     53\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 54\u001b[0;31m \u001b[0;32mdef\u001b[0m \u001b[0m_any\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0ma\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdtype\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mout\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkeepdims\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mwhere\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     55\u001b[0m     \u001b[0;31m# Parsing keyword arguments is currently fairly slow, so avoid it for now\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     56\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mwhere\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;31mKeyboardInterrupt\u001b[0m: "]}]},{"cell_type":"code","source":["!python -m spacy init fill-config /content/drive/My\\ Drive/base_config.cfg config.cfg"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"AHixaxL00DMO","executionInfo":{"status":"ok","timestamp":1700447258594,"user_tz":300,"elapsed":10876,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"fb88c9a3-19c1-47a4-ab3e-43e1b2c36ed9"},"execution_count":46,"outputs":[{"output_type":"stream","name":"stdout","text":["2023-11-20 02:27:30.310889: E tensorflow/compiler/xla/stream_executor/cuda/cuda_dnn.cc:9342] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n","2023-11-20 02:27:30.310951: E tensorflow/compiler/xla/stream_executor/cuda/cuda_fft.cc:609] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n","2023-11-20 02:27:30.310993: E tensorflow/compiler/xla/stream_executor/cuda/cuda_blas.cc:1518] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n","2023-11-20 02:27:32.146770: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT\n","\u001b[38;5;2m✔ Auto-filled config with all values\u001b[0m\n","\u001b[38;5;2m✔ Saved config\u001b[0m\n","config.cfg\n","You can now add your data and train your pipeline:\n","python -m spacy train config.cfg --paths.train ./train.spacy --paths.dev ./dev.spacy\n"]}]},{"cell_type":"code","source":["!python -m spacy init fill-config --help"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"Zei2v_zmq2B6","executionInfo":{"status":"ok","timestamp":1699979431747,"user_tz":300,"elapsed":6497,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"933d6af0-2f17-4c85-c74c-b56a69d51466"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["2023-11-14 16:30:27.061787: E tensorflow/compiler/xla/stream_executor/cuda/cuda_dnn.cc:9342] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n","2023-11-14 16:30:27.061856: E tensorflow/compiler/xla/stream_executor/cuda/cuda_fft.cc:609] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n","2023-11-14 16:30:27.061891: E tensorflow/compiler/xla/stream_executor/cuda/cuda_blas.cc:1518] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n","2023-11-14 16:30:28.220072: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT\n","\u001b[1m                                                                                                    \u001b[0m\n","\u001b[1m \u001b[0m\u001b[1;33mUsage: \u001b[0m\u001b[1mpython \u001b[0m\u001b[1;32m-m\u001b[0m\u001b[1m spacy init fill-config [OPTIONS] BASE_PATH [OUTPUT_FILE]\u001b[0m\u001b[1m                         \u001b[0m\u001b[1m \u001b[0m\n","\u001b[1m                                                                                                    \u001b[0m\n"," Fill partial config file with default values. Will add all missing settings from the default       \n"," config and will create all objects, check the registered functions for their default values and    \n"," update the base config. This command can be used with a config generated via the training          \n"," quickstart widget: https://spacy.io/usage/training#quickstart                                      \n"," \u001b[2mDOCS: https://spacy.io/api/cli#init-fill-config\u001b[0m                                                    \n","                                                                                                    \n","\u001b[2m╭─\u001b[0m\u001b[2m Arguments \u001b[0m\u001b[2m─────────────────────────────────────────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n","\u001b[2m│\u001b[0m \u001b[31m*\u001b[0m    base_path        \u001b[1;33mFILE         \u001b[0m  Path to base config to fill \u001b[2m[default: None]\u001b[0m \u001b[2;31m[required]\u001b[0m      \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m      output_file      \u001b[1;2;33m[\u001b[0m\u001b[1;33mOUTPUT_FILE\u001b[0m\u001b[1;2;33m]\u001b[0m  Path to output .cfg file (or - for stdout) \u001b[2m[default: -]\u001b[0m     \u001b[2m│\u001b[0m\n","\u001b[2m╰──────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n","\u001b[2m╭─\u001b[0m\u001b[2m Options \u001b[0m\u001b[2m───────────────────────────────────────────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n","\u001b[2m│\u001b[0m \u001b[1;36m-\u001b[0m\u001b[1;36m-pretraining\u001b[0m       \u001b[1;32m-pt\u001b[0m      \u001b[1;33m    \u001b[0m  Include config for pretraining (with 'spacy pretrain')        \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m \u001b[1;36m-\u001b[0m\u001b[1;36m-diff\u001b[0m              \u001b[1;32m-D\u001b[0m       \u001b[1;33m    \u001b[0m  Print a visual diff highlighting the changes                  \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m \u001b[1;36m-\u001b[0m\u001b[1;36m-code\u001b[0m\u001b[1;36m-path\u001b[0m,\u001b[1;36m-\u001b[0m\u001b[1;36m-code\u001b[0m  \u001b[1;32m-c\u001b[0m       \u001b[1;33mPATH\u001b[0m  Path to Python file with additional code (registered          \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m                                    functions) to be imported                                     \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m                                    \u001b[2m[default: None]                                              \u001b[0m \u001b[2m│\u001b[0m\n","\u001b[2m│\u001b[0m \u001b[1;36m-\u001b[0m\u001b[1;36m-help\u001b[0m                       \u001b[1;33m    \u001b[0m  Show this message and exit.                                   \u001b[2m│\u001b[0m\n","\u001b[2m╰──────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n","\n"]}]},{"cell_type":"code","source":["!python -m spacy train config.cfg --output ./ --paths.train ./train.spacy --paths.dev ./train.spacy"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"eLjTkDdV0Oay","executionInfo":{"status":"ok","timestamp":1700447291231,"user_tz":300,"elapsed":30165,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"bccff261-34b7-4cd4-b9ef-1ea7d32ee6dd"},"execution_count":47,"outputs":[{"output_type":"stream","name":"stdout","text":["2023-11-20 02:27:43.377907: E tensorflow/compiler/xla/stream_executor/cuda/cuda_dnn.cc:9342] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n","2023-11-20 02:27:43.377973: E tensorflow/compiler/xla/stream_executor/cuda/cuda_fft.cc:609] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n","2023-11-20 02:27:43.378008: E tensorflow/compiler/xla/stream_executor/cuda/cuda_blas.cc:1518] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n","2023-11-20 02:27:44.633389: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT\n","\u001b[38;5;4mℹ Saving to output directory: .\u001b[0m\n","\u001b[38;5;4mℹ Using CPU\u001b[0m\n","\u001b[1m\n","=========================== Initializing pipeline ===========================\u001b[0m\n","Traceback (most recent call last):\n","  File \"/usr/lib/python3.10/runpy.py\", line 196, in _run_module_as_main\n","    return _run_code(code, main_globals, None,\n","  File \"/usr/lib/python3.10/runpy.py\", line 86, in _run_code\n","    exec(code, run_globals)\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/__main__.py\", line 4, in <module>\n","    setup_cli()\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/cli/_util.py\", line 92, in setup_cli\n","    command(prog_name=COMMAND)\n","  File \"/usr/local/lib/python3.10/dist-packages/click/core.py\", line 1157, in __call__\n","    return self.main(*args, **kwargs)\n","  File \"/usr/local/lib/python3.10/dist-packages/typer/core.py\", line 778, in main\n","    return _main(\n","  File \"/usr/local/lib/python3.10/dist-packages/typer/core.py\", line 216, in _main\n","    rv = self.invoke(ctx)\n","  File \"/usr/local/lib/python3.10/dist-packages/click/core.py\", line 1688, in invoke\n","    return _process_result(sub_ctx.command.invoke(sub_ctx))\n","  File \"/usr/local/lib/python3.10/dist-packages/click/core.py\", line 1434, in invoke\n","    return ctx.invoke(self.callback, **ctx.params)\n","  File \"/usr/local/lib/python3.10/dist-packages/click/core.py\", line 783, in invoke\n","    return __callback(*args, **kwargs)\n","  File \"/usr/local/lib/python3.10/dist-packages/typer/main.py\", line 683, in wrapper\n","    return callback(**use_params)  # type: ignore\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/cli/train.py\", line 54, in train_cli\n","    train(config_path, output_path, use_gpu=use_gpu, overrides=overrides)\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/cli/train.py\", line 81, in train\n","    nlp = init_nlp(config, use_gpu=use_gpu)\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/training/initialize.py\", line 95, in init_nlp\n","    nlp.initialize(lambda: train_corpus(nlp), sgd=optimizer)\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/language.py\", line 1342, in initialize\n","    proc.initialize(get_examples, nlp=self, **p_settings)\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/pipeline/tok2vec.py\", line 213, in initialize\n","    validate_get_examples(get_examples, \"Tok2Vec.initialize\")\n","  File \"spacy/training/example.pyx\", line 74, in spacy.training.example.validate_get_examples\n","  File \"spacy/training/example.pyx\", line 53, in spacy.training.example.validate_examples\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/training/corpus.py\", line 164, in __call__\n","    for real_eg in examples:\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/training/corpus.py\", line 186, in make_examples\n","    for reference in reference_docs:\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/training/corpus.py\", line 221, in read_docbin\n","    for doc in docs:\n","  File \"/usr/local/lib/python3.10/dist-packages/spacy/tokens/_serialize.py\", line 151, in get_docs\n","    doc.cats = self.cats[i]\n","IndexError: list index out of range\n"]}]},{"cell_type":"code","source":["nlp_ner = spacy.load(\"model-best\")"],"metadata":{"id":"w0yjvERW1e_1","executionInfo":{"status":"ok","timestamp":1700444553596,"user_tz":300,"elapsed":2653,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}}},"execution_count":16,"outputs":[]},{"cell_type":"code","source":["doc = nlp_ner(\"Patient has severe leg pain. Patient is taking dosages of immunoglobulins. Patient is undergoing sling surgery.\")\n","\n","colors = {\"Condition\": \"#F67DE3\", \"Drug\": \"#7DF6D9\", \"Procedure\":\"#a6e22d\"}\n","options = {\"colors\": colors}\n","spacy.displacy.render(doc, style=\"ent\", options= options, jupyter=True)\n","\n","# print(doc.ents)\n","\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":123},"id":"6mZ7AkTP1ign","executionInfo":{"status":"ok","timestamp":1700444642546,"user_tz":300,"elapsed":184,"user":{"displayName":"Tomas Esber","userId":"06707006493259991549"}},"outputId":"ba2615bf-2888-4f05-9b75-33efaf282921"},"execution_count":17,"outputs":[{"output_type":"stream","name":"stderr","text":["/usr/local/lib/python3.10/dist-packages/spacy/displacy/__init__.py:213: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n","  warnings.warn(Warnings.W006)\n"]},{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.HTML object>"],"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Patient has severe leg pain. Patient is taking dosages of immunoglobulins. Patient is undergoing sling surgery.</div></span>"]},"metadata":{}},{"output_type":"stream","name":"stdout","text":["()\n"]}]}]}